var title_f24_0_24576="Allergic child PI";
var content_f24_0_24576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child with allergies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows a 4-year-old child with allergies. Children with severe allergies sometimes have dark circles under their eyes. They also tend to breathe with their mouth open because their nose&nbsp;is stuffy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24576=[""].join("\n");
var outline_f24_0_24576=null;
var title_f24_0_24577="Effects vitamin D and calcium supplementation on total fracture";
var content_f24_0_24577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 658px\">",
"   <div class=\"ttl\">",
"    Meta-analysis of randomized trials comparing the effects of combined vitamin D and calcium supplementation with placebo on total fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 638px; height: 483px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NS: not specified; NV: nonvertebral.",
"     <br>",
"      * Equally allocated groups.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Unequally allocated groups; 2 women were randomly assigned to the control group for every 1 woman randomly assigned to the treatment group.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung M, Lee J, Terasawa T, et al. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827. Copyright &copy; 2011 American College of Physicians. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24577=[""].join("\n");
var outline_f24_0_24577=null;
var title_f24_0_24578="Open oophorectomy b";
var content_f24_0_24578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open oophorectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After the ureter is identified, a window is created in the broad ligament and the ovarian vessels are doubly clamped and divided.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24578=[""].join("\n");
var outline_f24_0_24578=null;
var title_f24_0_24579="Distal colon wildtype mouse";
var content_f24_0_24579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal colon of a healthy wild-type mouse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal colon of a healthy wild-type mouse, universal Eub338 Cy3 probe, x400. Bacteria (orange fluorescence) are clearly separated from the colonic wall by a mucus layer. Bacterial concentrations within the colon are high. Water from the fecal stream softens the mucus layer, and mature mucus is carried away by the fecal stream. The mucus layer is continuously rebuilt, resulting in onion-like stratification on the border between stool and the mucus layer (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24579=[""].join("\n");
var outline_f24_0_24579=null;
var title_f24_0_24580="PCP in AIDS PA";
var content_f24_0_24580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumocystis jirovecii pneumonia in patient with AIDS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows diffuse ground glass opacification without air bronchograms and without obliteration of the pulmonary vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24580=[""].join("\n");
var outline_f24_0_24580=null;
var title_f24_0_24581="Patellar dislocations in children and adolescents";
var content_f24_0_24581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patellar dislocations in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Brian R Moore, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24581/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24581/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/0/24581/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellar dislocation occurs most often in the second and third decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Girls are affected more often than boys [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The usual mechanism of injury is a twisting movement about the knee as may occur during dancing, gymnastics, or the swinging of a baseball bat [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Direct trauma to the knee also may cause patellar dislocation. Lateral dislocation is most common; medial and intraarticular dislocations are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, evaluation, and management of lateral patellar dislocations in children and adolescents are reviewed here. Other knee injuries in young athletes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is a hinge joint between the femur and the tibia. The joint consists of three compartments that share a common synovial cavity: the medial tibiofemoral, lateral tibiofemoral, and patellofemoral. The capsule is strengthened by retinacula that are derived from the vastus muscles and expansion from the semimembranous tendon. The patella is a sesamoid bone embedded in the quadriceps tendon that articulates with the trochlear groove of the femur (",
"    <a class=\"graphic graphic_figure graphicRef51102 \" href=\"UTD.htm?20/6/20578\">",
"     figure 1",
"    </a>",
"    ). Its function is to increase the mechanical advantage of the quadriceps. The anatomy of the knee is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellar dislocation occurs most often in the second and third decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Girls are affected more often than boys [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The usual mechanism of injury is a twisting movement about the knee as may occur during dancing, gymnastics, or the swinging of a baseball bat [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Direct trauma to the knee also may cause patellar dislocation. Lateral dislocation is most common; medial and intraarticular dislocation are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The annual incidence of acute patellar dislocation in children younger than 16 years of age was calculated in a prospective two-year study to be",
"    <span class=\"nowrap\">",
"     43/100,000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/7\">",
"     7",
"    </a>",
"    ]. Associated osteochondral fractures were present in 39 percent of the children; these included capsular avulsions of the medial patellar margin and loose intraarticular fragments detached from the patella",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lateral femoral condyle.",
"   </p>",
"   <p>",
"    Data from a retrospective study of 270 patients and 284 knees with acute patellar dislocation indicated that 21 percent of cases were recurrent dislocations, 16 percent had a family history of dislocation, and 42 percent resulted from athletic performance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/8\">",
"     8",
"    </a>",
"    ]. The sporting events most commonly involved were soccer, gymnastics, and ice hockey.",
"   </p>",
"   <p>",
"    Patellar dislocation occurs as a familial trait with dominant inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. It also occurs as part of the Rubinstein Taybi (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=180849\">",
"     www.ncbi.nlm.nih.gov:80/entrez/dispomim.cgi?id=180849",
"    </a>",
"    ) and nail-patella syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=see_link&amp;anchor=H4#H4\">",
"     \"Nail-patella syndrome\", section on 'Extrarenal manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children younger than 15 years of age have a high rate of recurrence (up to 60 percent in some studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. In addition, certain conditions predispose to patellar instability and recurrent dislocation. These conditions include generalized joint laxity, passive lateral hypermobility of the patella, patellar subluxation, patella alta (high-riding patella), and below the knee amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,14-16\">",
"     1,14-16",
"    </a>",
"    ]. Individuals with these conditions have an increased incidence of recurrent and bilateral patellar dislocation, a decreased incidence of associated fractures, and occurrence of patellar dislocation with less significant trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lateral dislocation of the patella is usually obvious on clinical evaluation, unless the patella has reduced on its own with knee extension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/17\">",
"     17",
"    </a>",
"    ]. The patient describes severe pain and may have heard a pop or tear at the time of dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/5\">",
"     5",
"    </a>",
"    ]. The knee typically is held in 20 to 30 degrees of flexion and the patella is palpable laterally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional findings related to tearing of the restraining medial retinacular tissue and the medial patellofemoral ligament may include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An acutely swollen knee",
"     </li>",
"     <li>",
"      Hemarthrosis",
"     </li>",
"     <li>",
"      Tenderness to palpation along the medial edge of the patella",
"     </li>",
"     <li>",
"      Tenderness just proximal to the medial femoral epicondyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not necessary to obtain radiographs of the knee before reduction unless the diagnosis is in question.",
"   </p>",
"   <p>",
"    Patellar subluxation, rather than dislocation, may have occurred if the history is consistent with dislocation, but the pain and abnormal examination findings have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/4\">",
"     4",
"    </a>",
"    ]. Clues to patellar subluxation include a high-riding patella (patella alta) or laterally displaced patella. Lateral patellar displacement or subluxation may be observed as the seated patient straightens the knee and the patella moves outward instead of straight upward; this is often called the \"J\" sign.",
"   </p>",
"   <p>",
"    Patients with patellar subluxation should have knee radiographs to rule out an associated avulsion fracture of the patella or femoral condyle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REDUCTION OF PATELLAR DISLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual reduction is necessary if the dislocated patella fails to reduce spontaneously. Immediate reduction may be attempted if the dislocation is recent (ie, on the playing field) or witnessed. Patients who present to the emergency department may require pain control and sedation before reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once adequate analgesia is achieved, the patient is placed in the supine position with the hips flexed to relax the quadriceps muscles. The knee is slowly extended while medial pressure is applied to the lateral aspect of the dislocated patella (",
"    <a class=\"graphic graphic_figure graphicRef64758 \" href=\"UTD.htm?17/26/17839\">",
"     figure 2",
"    </a>",
"    ). Successful reduction is indicated by the return of the patella to the tibiofemoral tract and normal function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/20\">",
"     20",
"    </a>",
"    ]. Knee effusion may occur after the reduction or may remain if it was present before the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AP, lateral, and patellar (\"sunrise\" or \"tunnel\" view) knee radiographs should be obtained after the reduction to assess for fracture or avulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Associated osteochondral fractures occur in up to 39 percent of children with patellar dislocation and often require MRI for detection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the patient should undergo evaluation for other ligamentous injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSTREDUCTION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After reduction and complete evaluation, the knee should be placed in a patellar stabilizing brace or in a knee immobilizer until a brace may be obtained. In addition, the patient should use crutches to assist with ambulation. Nonsteroidal antiinflammatory medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 800 mg) may be used as needed for pain control. Rest, ice, compression, and elevation are recommended as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/6,19-21\">",
"     6,19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limit walking, standing, impact, and repetitive bending, particularly if these activities cause pain.",
"     </li>",
"     <li>",
"      Apply ice and elevate the leg for 10 to 15 minutes four times daily.",
"     </li>",
"     <li>",
"      Use a patellar restraining brace with fabric stays during the day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with patellar dislocation should have follow-up with their primary care physician or an orthopedic surgeon five to seven days after the initial injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postreduction treatment for children and adolescents who have a first time lateral dislocation with normal radiograph and normal patellofemoral alignment is aimed at regaining quadriceps strength and protecting against subsequent dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/22\">",
"     22",
"    </a>",
"    ]. The emphasis in early rehabilitation should be on improving range of motion, especially knee flexion, and decreasing edema and swelling.",
"   </p>",
"   <p>",
"    Athletes with acute patellar dislocation can expect to return to play within four to six weeks with appropriate strengthening exercises and the use of a knee brace [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/23\">",
"     23",
"    </a>",
"    ]. The treatment of young patients with knee injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inability to reduce the patella, suspicion of fracture, fracture, atypical dislocation (medial or intraarticular), or ligamentous injury should prompt an immediate orthopedic consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children younger than 15 years of age recurrence approaches 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/24\">",
"     24",
"    </a>",
"    ]. Orthopedic or sports medicine referral is warranted in patients with contralateral patellofemoral instability (positive apprehension test) or a family history of patellar dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Rehabilitation alone appears to be as effective as operative treatment followed by rehabilitation in children under 16 years of age with patellofemoral instability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A demonstration video that shows a successful patellar dislocation reduction is available as supporting information for the online version of the reference [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24581/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patellar dislocation occurs most often in the second and third decades of life. Girls are affected more often than boys, and the dislocation is typically lateral. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute lateral dislocation of the patella is usually obvious on clinical evaluation. The knee typically is held in 20 to 30 degrees of flexion and the patella is palpable laterally. Additional findings may include (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An acutely swollen knee",
"     </li>",
"     <li>",
"      Hemarthrosis",
"     </li>",
"     <li>",
"      Tenderness to palpation along the medial edge of the patella",
"     </li>",
"     <li>",
"      Tenderness just proximal to the medial femoral epicondyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reduction may be attempted if the dislocation is recent (ie, on the playing field) or witnessed. Patients who present to the emergency department may require pain control and sedation before reduction. It is not necessary to obtain radiographs of the knee before reduction unless the diagnosis is in question. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reduction of patellar dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once adequate analgesia is achieved, the patient is placed in the supine position with the hips flexed to relax the quadriceps muscles. The knee is slowly extended while medial pressure is applied to the lateral aspect of the dislocated patella (",
"      <a class=\"graphic graphic_figure graphicRef64758 \" href=\"UTD.htm?17/26/17839\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reduction of patellar dislocation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful reduction is indicated by the return of the patella to the tibiofemoral tract and normal function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reduction of patellar dislocation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AP, lateral, and patellar (\"sunrise\" or \"tunnel\" view) knee radiographs should be obtained after the reduction to assess for fracture or avulsion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postreduction management consists of splinting with a patellar stabilizing brace or knee immobilizer, measures to decrease inflammation, and rehabilitation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Postreduction management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/1\">",
"      Cash JD, Hughston JC. Treatment of acute patellar dislocation. Am J Sports Med 1988; 16:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/2\">",
"      Cofield RH, Bryan RS. Acute dislocation of the patella: results of conservative treatment. J Trauma 1977; 17:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/3\">",
"      Atkin DM, Fithian DC, Marangi KS, et al. Characteristics of patients with primary acute lateral patellar dislocation and their recovery within the first 6 months of injury. Am J Sports Med 2000; 28:472.",
"     </a>",
"    </li>",
"    <li>",
"     Baskin MN. Injury-knee. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.383.",
"    </li>",
"    <li>",
"     Patellofemoral instability and malalignment. In: Essentials of Musculoskeletal Care, 2nd, Green WB.  (Ed), American Academy of Orthopedic Surgeons, Rosemont 2001. p.387.",
"    </li>",
"    <li>",
"     Young GM. Reduction of common joint dislocations and subluxations. In: Textbook of Pediatric Emergency Procedures, Henretig RM, King C.  (Eds), Williams &amp; Wilkins, Baltimore 1997. p.1088.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/7\">",
"      Nietosvaara Y, Aalto K, Kallio PE. Acute patellar dislocation in children: incidence and associated osteochondral fractures. J Pediatr Orthop 1994; 14:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/8\">",
"      M&auml;enp&auml;&auml; H, Lehto MU. Surgery in acute patellar dislocation--evaluation of the effect of injury mechanism and family occurrence on the outcome of treatment. Br J Sports Med 1995; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/9\">",
"      Borochowitz Z, Soudry M, Mendes DG. Familial recurrent dislocation of patella with autosomal dominant mode of inheritance. Clin Genet 1988; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/10\">",
"      Carter, C. Sweetnam, R. Recurrent dislocation of the patella and of the shoulder: their association with familial joint laxity. J Bone Joint Surg 1960; 42B:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/11\">",
"      Miller GF. Familial recurrent dislocation of the patella. J Bone Joint Surg Br 1978; 60-B:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/12\">",
"      Stevens CA. Patellar dislocation in Rubenstein-Taybi syndrome. Am J Med Genet 1997; 72:188.",
"     </a>",
"    </li>",
"    <li>",
"     Tolo V. Fractures and dislocations about the knee. In: Skeletal Trauma in Children, Green NE, Swiontkowski MF.  (Eds), WB Saunders, Philadelphia 1998. p.453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/14\">",
"      R&uuml;now A. The dislocating patella. Etiology and prognosis in relation to generalized joint laxity and anatomy of the patellar articulation. Acta Orthop Scand Suppl 1983; 201:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/15\">",
"      Larsen E, Lauridsen F. Conservative treatment of patellar dislocations. Influence of evident factors on the tendency to redislocation and the therapeutic result. Clin Orthop Relat Res 1982; :131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/16\">",
"      Mowery CA, Herring JA, Jackson D. Dislocated patella associated with below-knee amputation in adolescent patients. J Pediatr Orthop 1986; 6:299.",
"     </a>",
"    </li>",
"    <li>",
"     Ogden JA. Knee. In: Skeletal Injury in the Child, Ogden JA.  (Ed), Springer-Verlag, New York 2000. p.938.",
"    </li>",
"    <li>",
"     Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, 3rd, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1525.",
"    </li>",
"    <li>",
"     Ruddy RM. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1861.",
"    </li>",
"    <li>",
"     Ludwig S. Dislocations, subluxations, and diastasis. In: Illustrated Textbook of Pediatric Emergency and Critical Care Procedures, Dieckman RA, Fiser DH, Selbst SM.  (Eds), Mosby, St. Louis 1997. p.630.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/21\">",
"      M&auml;enp&auml;&auml; H, Lehto MU. Patellar dislocation. The long-term results of nonoperative management in 100 patients. Am J Sports Med 1997; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     Garrick JG, Webb DR. Knee injuries. In: Sport Injuries: Diagnosis and Management, 2nd, WB Saunders, Phladelphia 1992. p.259.",
"    </li>",
"    <li>",
"     Kibler WB. The knee. In: American College of Sports Medicine's Handbook for the Team Physician, Williams &amp; Wilkins, Baltimore 1996. p.324.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/24\">",
"      Palmu S, Kallio PE, Donell ST, et al. Acute patellar dislocation in children and adolescents: a randomized clinical trial. J Bone Joint Surg Am 2008; 90:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24581/abstract/25\">",
"      Lu DW, Wang EE, Self WH, Kharasch M. Patellar dislocation reduction. Acad Emerg Med 2010; 17:226.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6309 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24581=[""].join("\n");
var outline_f24_0_24581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REDUCTION OF PATELLAR DISLOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSTREDUCTION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6309|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/6/20578\" title=\"figure 1\">",
"      Sagittal knee anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/26/17839\" title=\"figure 2\">",
"      Patellar reduction technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=related_link\">",
"      Nail-patella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=related_link\">",
"      Treatment of knee injuries in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24582="NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome";
var content_f24_0_24582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24582/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/0/24582/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAID) can induce two different forms of acute kidney injury: hemodynamically-mediated; and acute interstitial nephritis, which is often accompanied by the nephrotic syndrome. The former and perhaps the latter are directly related to the reduction in prostaglandin synthesis induced by the NSAID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMODYNAMICALLY-MEDIATED ACUTE KIDNEY INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal prostaglandins are primarily vasodilators, they do not play a major role in the regulation of renal hemodynamics in normal subjects, since the basal rate of prostaglandin synthesis is relatively low. By contrast, the release of these hormones (particularly prostacyclin and prostaglandin E2) is increased by underlying glomerular disease, renal insufficiency, hypercalcemia, and the vasoconstrictors angiotensin II and norepinephrine. The secretion of the latter hormones is increased in states of effective volume depletion, such as heart failure, cirrhosis, and true volume depletion due to gastrointestinal or renal salt and water losses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=see_link\">",
"     \"Chapter 6E: Prostaglandins and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these settings, vasodilator prostaglandins act to preserve renal blood flow and glomerular filtration rate by relaxing preglomerular resistance. This is particularly important with effective volume depletion in which the prostaglandins antagonize the vasoconstrictor effects of angiotensin II and norepinephrine. In glomerular disease, however, the increase in prostaglandin production seems to maintain the glomerular filtration rate in the presence of an often marked reduction in glomerular capillary permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of prostaglandin synthesis with an NSAID in such patients can lead to reversible renal ischemia, a decline in glomerular hydraulic pressure (the major driving force for glomerular filtration), and acute kidney injury (",
"    <a class=\"graphic graphic_figure graphicRef78038 \" href=\"UTD.htm?10/25/10653\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/1-4,6\">",
"     1-4,6",
"    </a>",
"    ]. The rise in the plasma creatinine concentration is seen within the first three to seven days of therapy, the time required for attainment of steady state drug levels and therefore maximum inhibition of prostaglandin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute kidney injury can occur with any NSAID [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/1,2,8,9\">",
"     1,2,8,9",
"    </a>",
"    ]. A nested case-control study correlated hospitalization with a diagnosis of acute kidney injury with the initiation of NSAID use among 121,722 elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/9\">",
"     9",
"    </a>",
"    ]. Compared with unexposed individuals, an increased risk of acute kidney injury within 30 days of NSAID initiation was noted with the nonselective NSAIDs other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (RR of 2.3), naproxen (RR of 2.4), rofecoxib (RR 2.3), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (RR of 1.5).",
"   </p>",
"   <p>",
"    There has been concern that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    might have greater nephrotoxic potential than other NSAIDs. A retrospective analysis of over 10,000 courses of ketorolac in 35 hospitals attempted to assess how frequently it produced a decline in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/10\">",
"     10",
"    </a>",
"    ]. Acute kidney injury was defined as an elevation in the plasma creatinine concentration of 50 percent or more or an absolute rise of 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44.2",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    When compared to control patients treated with opioids (which are not nephrotoxic), those treated with ketorolac for less than five days had the same risk of renal failure. Patients treated for more than five days had a relative risk of 2.1, but the overall incidence was only 1 percent.",
"   </p>",
"   <p>",
"    The selective COX-2 inhibitors also may precipitate acute kidney injury in certain patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is suggestive evidence that some nonselective NSAIDs have a lower nephrotoxic potential than others. Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (studied at approximately 40 mg per day), low-dose over-the-counter",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and perhaps",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    appear to be safer; one proposed mechanism is relative sparing of renal prostaglandin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&mdash; With",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the inhibition of glomerular cyclooxygenase may only be partial and transient, in contrast to the irreversible acetylation in platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. However, even low-dose aspirin in elderly patients or aspirin used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (and possibly other NSAIDS), may lead to a decline in kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&mdash; Over-the-counter",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    in low doses is safe in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/17\">",
"     17",
"    </a>",
"    ]. However, even low dose ibuprofen can reduce the glomerular filtration rate in patients with reduced renal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&mdash; The mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    might spare renal prostaglandin synthesis is not well understood. Both a lesser degree of general cyclooxygenase inhibition and rapid renal metabolism (resulting in little or no free drug being excreted in the urine) have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/2,6,18,19\">",
"     2,6,18,19",
"    </a>",
"    ]. In addition, some have suggested that sulindac has similar renal effects as other NSAIDs.",
"   </p>",
"   <p>",
"    At the least, careful monitoring is still required. Renal protection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    is not absolute and careful monitoring is still required, since significant reductions in glomerular filtration rate have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]. This interpatient variability may be related in part to differences (genetic or environmental) in the rate of renal oxidation of the active metabolite sulindac sulfide. Approximately 65 percent of people excrete no sulindac sulfide in the urine and may be at low risk for side effects related to renal cyclooxygenase inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/19\">",
"     19",
"    </a>",
"    ]. A sulindac-induced decline in renal function may be most likely to occur in patients who do excrete the active metabolite in the urine. There is, however, no simple way to identify these patients in advance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407516\">",
"    <span class=\"h2\">",
"     NSAID-induced vasoconstriction and risk of acute tubular necrosis (ATN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NSAID-induced inhibition of prostaglandin-mediated afferent vasodilation may increase the risk for acute tubular necrosis (ATN) caused by ischemia or other nephrotoxins, such as radiocontrast media [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of contrast-induced nephropathy\", section on 'Inhibition of renal vasoconstriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a rule, patients should discontinue NSAIDs prior to procedures that involve the administration of iodinated contrast media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE INTERSTITIAL NEPHRITIS AND NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second form of NSAID-induced acute kidney injury has two components, one or both of which may be present in a given patient: an acute interstitial nephritis, with an interstitial infiltrate composed primarily of T lymphocytes; and the nephrotic syndrome due to minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The latter may be due to release of a toxic lymphokine from the activated T cells.",
"   </p>",
"   <p>",
"    This disorder is most likely to occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/52/27464?source=see_link\">",
"     fenoprofen",
"    </a>",
"    , but probably can be induced by any nonselective NSAID. There have also been case reports of selective COX-2 inhibitors also being associated with this pattern of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How NSAIDs produce acute interstitial nephritis and nephrotic syndrome are not known; it is possible that cyclooxygenase inhibition by the NSAID results in the preferential conversion of arachidonic acid to leukotrienes, which can then activate helper T cells.",
"   </p>",
"   <p>",
"    Affected patients typically present with hematuria, pyuria, white cell casts, proteinuria, and an acute rise in the plasma creatinine concentration. The full picture of an allergic reaction &mdash; fever, rash, eosinophilia, and eosinophiluria &mdash; is typically absent but one or more of these findings may be present. Spontaneous recovery generally occurs within weeks to a few months after therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. All NSAIDS should be terminated in patients suspected of having NSAID-induced acute interstitial nephritis. Since topically administered NSAIDs can be systemically absorbed, such therapy should also be terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no definitive evidence that corticosteroid therapy is beneficial in this setting. However, a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be considered in patients whose renal failure persists more than 1 to 2 weeks after the NSAID has been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"     \"Treatment of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients should avoid the subsequent administration of NSAIDs. Relapse may occur with rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial reports found that virtually all cases of NSAID-induced nephrotic syndrome that were biopsied had minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], it is now evident that membranous nephropathy can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Many of the patients who developed membranous nephropathy were treated with a specific NSAID,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , but probably any NSAID can be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report suggested that NSAID-induced membranous nephropathy may be much more common than previously appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24582/abstract/30\">",
"     30",
"    </a>",
"    ]. This study evaluated 125 patients with early disease: 29 were taking an NSAID and 13 (10 percent) fulfilled three criteria strongly suggesting that the NSAID was responsible:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No other apparent cause for the membranous nephropathy",
"     </li>",
"     <li>",
"      Resolution of the proteinuria within weeks to months after the cessation of therapy",
"     </li>",
"     <li>",
"      No recurrence of proteinuria at follow-up ranging from 5 months to 13 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above acute effects, it has been proposed that daily NSAID use for a prolonged period of time may be associated with an increased risk of chronic kidney disease, perhaps due to papillary necrosis similar to that seen with other analgesics. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=see_link\">",
"     \"Risk factors for and pathogenesis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407606\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAID) can induce both hemodynamically-mediated acute kidney injury and acute interstitial nephritis, occasionally accompanied by the nephrotic syndrome. Both may be related to the reduction in prostaglandin synthesis induced by the NSAID. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prostaglandins preserve renal blood flow and glomerular filtration rate by decreasing preglomerular resistance in the setting of real or effective volume depletion. The NSAID-induced inhibition of prostaglandin synthesis can lead to reversible renal ischemia or a decline in glomerular hydraulic pressure resulting in acute kidney injury in such patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hemodynamically-mediated acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute kidney injury can occur with any NSAID, as well as the selective COX-2 inhibitors. Some nonselective NSAIDs may be less nephrotoxic than others. The less nephrotoxic NSAIDs include low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , low-dose over-the-counter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , and possibly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"       sulindac",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hemodynamically-mediated acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The NSAID-induced inhibition of prostaglandin-mediated afferent vasodilation may increase the risk for acute tubular necrosis (ATN) caused by ischemia or other nephrotoxins, such as radiocontrast media. Patients should not take NSAIDs prior to procedures that involve the administration of iodinated contrast media. (See",
"      <a class=\"local\" href=\"#H2407516\">",
"       'NSAID-induced vasoconstriction and risk of acute tubular necrosis (ATN)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAID) may also cause acute interstitial nephritis and the nephrotic syndrome. The nephrotic syndrome is usually due to minimal change disease but membranous nephropathy has also been reported. Acute interstitial nephritis and the nephrotic syndrome may occur in the same patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute interstitial nephritis and nephrotic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present with acute interstitial nephritis typically present with hematuria, pyuria, white cell casts, proteinuria, and an acute rise in the plasma creatinine concentration. Spontaneous recovery generally occurs within weeks to a few months after therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute interstitial nephritis and nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"       \"Treatment of acute interstitial nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All NSAIDs, including topically administered forms, should be terminated in patients suspected of having NSAID-induced acute interstitial nephritis. Although there is no definitive evidence that corticosteroid therapy is beneficial in this setting, a course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      may be considered in patients whose renal failure persists more than one to two weeks after the NSAID has been discontinued. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute interstitial nephritis and nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"       \"Treatment of acute interstitial nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Daily NSAID use for a prolonged period of time may be associated with an increased risk of chronic kidney disease, perhaps due to papillary necrosis similar to that seen with other analgesics. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=see_link\">",
"       \"Risk factors for and pathogenesis of analgesic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/1\">",
"      Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/2\">",
"      Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 192-196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/4\">",
"      Huerta C, Castellsague J, Varas-Lorenzo C, Garc&iacute;a Rodr&iacute;guez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/5\">",
"      Takahashi K, Schreiner GF, Yamashita K, et al. Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat. J Clin Invest 1990; 85:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/6\">",
"      Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/7\">",
"      Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990; 112:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/8\">",
"      Haragsim L, Dalal R, Bagga H, Bastani B. Ketorolac-induced acute renal failure and hyperkalemia: report of three cases. Am J Kidney Dis 1994; 24:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/9\">",
"      Schneider V, L&eacute;vesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006; 164:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/10\">",
"      Feldman HI, Kinman JL, Berlin JA, et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/11\">",
"      Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/12\">",
"      Dunn MJ. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/13\">",
"      Braden GL, O'Shea MH, Mulhern JG, Germain MJ. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004; 19:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/14\">",
"      Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/15\">",
"      Segal R, Lubart E, Leibovitz A, et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med 2003; 115:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/16\">",
"      Pamuk ON, Cakir N. The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clin Rheumatol 2006; 25:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/17\">",
"      Mann JF, Goerig M, Brune K, Luft FC. Ibuprofen as an over-the-counter drug: is there a risk for renal injury? Clin Nephrol 1993; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/18\">",
"      Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 1986; 90:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/19\">",
"      Brandli DW, Sarkissian E, Ng SC, Paulus HE. Individual variability in concentrations of urinary sulindac sulfide. Clin Pharmacol Ther 1991; 50:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/20\">",
"      Brater DC, Anderson SA, Brown-Cartwright D, Toto RD. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis 1986; 8:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/21\">",
"      Spargias K, Adreanides E, Demerouti E, et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2009; 120:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/22\">",
"      Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/23\">",
"      Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/24\">",
"      Warren GV, Korbet SM, Schwartz MM, Lewis EJ. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1989; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/25\">",
"      Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/26\">",
"      Andrews PA, Sampson SA. Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Nephrol Dial Transplant 1999; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/27\">",
"      Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/28\">",
"      Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. Clin Nephrol 2000; 53:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/29\">",
"      Campistol JM, Galofre J, Botey A, et al. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24582/abstract/30\">",
"      Radford MG Jr, Holley KE, Grande JP, et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7230 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24582=[""].join("\n");
var outline_f24_0_24582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2407606\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMODYNAMICALLY-MEDIATED ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2407516\">",
"      NSAID-induced vasoconstriction and risk of acute tubular necrosis (ATN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE INTERSTITIAL NEPHRITIS AND NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2407606\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7230|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10653\" title=\"figure 1\">",
"      NSAID lowers GFR in cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=related_link\">",
"      Chapter 6E: Prostaglandins and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=related_link\">",
"      Risk factors for and pathogenesis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=related_link\">",
"      Treatment of acute interstitial nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24583="Laparoscopic surgery for ovulation induction in polycystic ovary syndrome";
var content_f24_0_24583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Barry W Donesky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24583/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/0/24583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularity and evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern balding) or biochemical (elevated serum androgen level). The majority of women who have infertility associated with chronic anovulation in this disorder ovulate in response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/1\">",
"     1",
"    </a>",
"    ]. However, up to 30 percent remain anovulatory. Furthermore, of the roughly 70 percent who do ovulate in response to clomiphene citrate, only one-half will conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although some women who are resistant to clomiphene alone are able to ovulate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (alone or combined with clomiphene), there are still women who are unresponsive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    combined with clomiphene, the next step has been gonadotropin therapy. While this treatment causes ovulation in most women, it has several potential problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can be very difficult to titrate the dose of gonadotropins to achieve monofollicular ovulation.",
"     </li>",
"     <li>",
"      The high frequency of multifollicular ovulation results in multiple gestations in 30 percent or more of women [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of ovarian hyperstimulation syndrome (OHSS) during gonadotropin administration is substantial, necessitating careful monitoring during treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=see_link\">",
"       \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The costs of therapy are high, especially considering that only one ovulatory event will occur with each course of treatment.",
"     </li>",
"     <li>",
"      For those women who do become pregnant, the frequency of spontaneous abortion appears to be higher than when conception occurs after spontaneous ovulation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of laparoscopic surgery for ovulation induction in PCOS will be reviewed here. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , gonadotropins, and aromatase inhibitors for ovulation induction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches to restoring ovulation in women with PCOS date back to the 1930s [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/5\">",
"     5",
"    </a>",
"    ], when bilateral ovarian wedge resection was found to result in restoration of regular menses and pregnancy. While undoubtedly effective in producing ovulatory cycles in previously anovulatory women, bilateral ovarian wedge resection fell out of favor due to postoperative adhesion formation and the introduction of ovulation-inducing medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate.",
"   </p>",
"   <p>",
"    Advocates of laparoscopic surgery have long claimed that procedures carried out laparoscopically result in less postoperative adhesion formation as compared with laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Modern developments in operative laparoscopy led to renewed interest in this approach to ovarian resection for ovulation induction.",
"   </p>",
"   <p>",
"    The literature now contains reports of over 1000 women in whom partial ovarian resection or ablation was done via a laparoscopic approach in the hope of restoring some ovulatory function. Pregnancy has occurred in approximately 55 percent of women undergoing this procedure, a figure that compares favorably with conception rates after three to six cycles of gonadotropin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/9\">",
"     9",
"    </a>",
"    ]. While these comparisons have been largely from uncontrolled case series, randomized controlled trials suggest that ovarian diathermy (electrocautery), when compared to gonadotropin therapy, results in similar success rates, but lower multiple gestation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endocrine changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;After laparoscopic surgery to restore ovulation, serum androstenedione concentrations fall transiently and serum luteinizing hormone (LH), testosterone, and inhibin concentrations fall more permanently [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Conversely, serum follicle-stimulating hormone (FSH) concentrations rise. The net effect is normalization of some of the endocrine abnormalities associated with the polycystic ovary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=see_link\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 17 women with PCOS, serum androgen concentrations decreased following laparoscopic ovarian cautery, without changes in insulin sensitivity or lipoprotein levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, in a second study in 12 women with PCOS, insulin resistance improved after laparoscopic ovarian cautery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/19\">",
"     19",
"    </a>",
"    ]. The improvement appeared to be due to a reduction in insulin receptor serine phosphorylation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism(s) by which controlled partial destruction of the ovary results in follicle development and ovulation is unknown. While the hormonal changes probably contribute, it is not clear that they are the sole mechanism for restoration of ovulation. The wedge resection technique mainly destroys stromal (androgen-producing) elements; however, other procedures, such as ultrasound-guided transvaginal aspiration of the follicles, appear to produce similar results while having a minimal effect on the stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/20\">",
"     20",
"    </a>",
"    ]. The most plausible mechanism involves a sudden drop in intraovarian androgens (and perhaps estrogens) that results in increased FSH secretion and an intrafollicular environment more conducive to normal follicular maturation and ovulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods of laparoscopic treatment have been studied, including electrocautery (also known as diathermy), laser \"drilling,\" and multiple biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/9\">",
"     9",
"    </a>",
"    ]. Each share a common goal of creating focal areas of damage in the ovarian cortex and stroma. There is no evidence that one method consistently produces superior clinical results; thus, for practical purposes they can be viewed as equivalent procedures. The most extensively studied procedure has been that of electrocautery, which is used to create thermal damage and necrosis of the \"excess\" ovarian stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the development of laparoscopic laser delivery systems, it was inevitable that this modality would also be applied [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/22\">",
"     22",
"    </a>",
"    ]. The technique is similar to that of electrocautery, as the ovarian cortex over follicles is vaporized. Since lasers focus their energy more precisely than electrocautery, less peripheral thermal damage is inflicted. As is the case with electrocautery, the laser-induced lesions are placed away from the tubo-ovarian interface to minimize adhesions in this area.",
"   </p>",
"   <p>",
"    Although the literature suggests that laser cautery is as effective as electrocautery, the laser is becoming less popular in PCOS. The reasons seem to center on concerns about the amount of ovarian surface damage and the potential for adhesion formation after laser treatment (personal communications).",
"   </p>",
"   <p>",
"    The more popular method at this time is the use of a unipolar needle electrode that is insulated proximal to the distal 1 or 2 centimeters. Four to six punctures of each ovary can produce substantial thermal damage to the stromal compartment while, in theory, producing minimal surface damage, and a minimal amount of adhesion formation. As an example, in one retrospective study of 112",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant women treated with insulated needle cautery, the cumulative pregnancy rate at 12, 18, and 24 months was 54, 68, and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/23\">",
"     23",
"    </a>",
"    ]. The miscarriage rate was about 8 percent.",
"   </p>",
"   <p>",
"    The author of this topic review prefers the unipolar needle electrode because of the ease of set-up and the wide availability of the equipment needed. The procedure is performed using the needle electrode through a midline suprapubic port, trying to direct most of the punctures from the end of the ovary nearest the uterus and from the side of the ovary that normally lies next to the pelvic sidewall. This keeps the surface damage away from the fallopian tube as much as possible.",
"   </p>",
"   <p>",
"    More recently, transvaginal hydrolaparoscopy has been utilized to perform ovarian drilling resulting in an even less invasive procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of 15 women who underwent a second-look laparoscopy, 11 women were found to be free of adhesions. Four women had periadnexal adhesions that were filmy, minimal, and found on the ovarian surface only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to providing similar conception rates to those of gonadotropin therapy, the laparoscopic approach may offer several other advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Safe gonadotropin administration requires intensive, expensive and time-consuming monitoring, while virtually no cyclic monitoring of ovulation is required in women treated surgically.",
"     </li>",
"     <li>",
"      Surgical therapy may be more cost-effective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/12,26\">",
"       12,26",
"      </a>",
"      ], because one treatment, in principle, results in several ovulatory cycles, whereas one course of gonadotropin therapy yields a single ovulatory cycle.",
"     </li>",
"     <li>",
"      There appears to be no increased risk of multiple gestation or ovarian hyperstimulation with the surgical procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/10-14\">",
"       10-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy rates after laparoscopic surgery appear to be similar to what has been reported for gonadotropin therapy. In one review, the six-month cumulative pregnancy rate after laparoscopic ovulation induction procedures was 55 percent (range 20 to 65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The spontaneous abortion rate was lower than after the medical induction of ovulation in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/27,28\">",
"       27,28",
"      </a>",
"      ], but not in the meta-analysis described below [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of the advantages and disadvantages of laparoscopic surgery and of gonadotropin therapy for ovulation induction is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef82084 \" href=\"UTD.htm?9/11/9404\">",
"     table 1",
"    </a>",
"    ). The major advantages of surgery relate to the relative simplicity and efficacy of the procedure. The risks are those of anesthesia, injury to the bowel, bladder, and major blood vessels, infection, and postoperative adhesion formation.",
"   </p>",
"   <p>",
"    In a series of more than 200 women with PCOS treated by laparoscopic ovarian electrocautery, nearly all had regular menstrual periods for prolonged periods after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/29\">",
"     29",
"    </a>",
"    ]. However, its long-term effects are not known, and it therefore seems prudent to recommend the laparoscopic approach only to women actively seeking pregnancy. In addition, more recent advances in our understanding of the relationship of insulin resistance and PCOS have shown that the administration of insulin sensitizing agents will allow many women previously resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate to ovulate spontaneously or with the addition of clomiphene citrate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best evidence to date that laparoscopic \"drilling\" by diathermy or laser is effective for ovulation induction comes from a systematic review and meta-analysis of six randomized trials in 353",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/12\">",
"     12",
"    </a>",
"    ]. When laparoscopic surgery was compared to gonadotropin therapy, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After 12 months of follow-up, laparoscopic surgery and gonadotropin therapy resulted in similar rates of ovulation (52 versus 62 percent; OR 0.66, 95% CI 0.21-2.07).",
"     </li>",
"     <li>",
"      No significant differences were seen in ongoing pregnancy rates between the two treatments (OR 1.15, 95% CI 0.69-1.93 for surgery versus gonadotropin therapy).",
"     </li>",
"     <li>",
"      No cases of ovarian hyperstimulation were reported in the trials for either laparoscopic surgery or gonadotropin therapy.",
"     </li>",
"     <li>",
"      Lower rates of multiple gestation were see with laparoscopic surgery when compared to gonadotropin therapy (OR 0.13, 95% CI 0,03-0.59)",
"     </li>",
"     <li>",
"      The cost per pregnancy appeared to be lower with surgery (possibly due to the lower multiple gestation rate).",
"     </li>",
"     <li>",
"      No differences were seen in miscarriage rates between laparoscopic surgery or gonadotropin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials have reported that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy (combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    in one trial) was similar to laparoscopic ovarian diathermy for inducing ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]; one trial reported that metformin therapy was better for overall reproductive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, insulin sensitizing agents should be considered in an effort to maximize the responsiveness to clomiphene citrate prior to performing the laparoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study, 140",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate-resistant women were randomized to receive ovarian drilling or six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    for ovulation induction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/34\">",
"     34",
"    </a>",
"    ]. The author found that letrozole was superior in producing ovulation, as well as finding a statistically non-significant trend toward a higher pregnancy rate and a lower miscarriage rate. The authors suggest that letrozole be used prior to resort to ovarian drilling.",
"   </p>",
"   <p>",
"    Other important considerations for laparoscopic surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be of normal weight, because the procedure is often unsuccessful in obese women (body mass index &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      body surface area) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/29,35\">",
"       29,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women should have no additional infertility factors. When PCOS is the only cause of infertility, 80 to 87 percent become pregnant after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/29,36\">",
"       29,36",
"      </a>",
"      ]. In contrast, the pregnancy rates are only 14 to 29 percent in women who also have an additional tubal factor, endometriosis, or an oligospermic male partner [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With its increasing success, in vitro fertilization has now become a viable option for PCOS patients. Excellent pregnancy rates are obtained, while the ability to control the number of embryos replaced allows multiple pregnancy rates to be controlled [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POTENTIAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports on laparoscopic surgery to allow ovulation in women with PCOS have been favorable. However, several have raised some serious issues. Most women who had the procedure were found to have adhesions when a second-look laparoscopy was performed later [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], although the adhesions did not appear to cause problems relating to conception. There is one report of unilateral ovarian atrophy after laparoscopic ovarian electrocautery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data regarding the relationship between laparoscopic ovulation induction procedures and menopause. However, an epidemiologic study demonstrated earlier menopause in women who underwent ovarian reductive surgery of any type [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/42\">",
"     42",
"    </a>",
"    ]. The women having the earliest menopause (nearly 10 years earlier than in normal women) were those who had undergone bilateral ovarian wedge resection before age 30.",
"   </p>",
"   <p>",
"    One study reported a decrease in anti-m&uuml;llerian hormone (AMH) in women who underwent ovarian drilling [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24583/abstract/43\">",
"     43",
"    </a>",
"    ]. While potentially providing a way to assess adequacy of treatment, this finding underscores the fact that these are destructive procedures that result in the loss of oocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In anovulatory women with polycystic ovarian syndrome (PCOS), initial interventions to induce ovulation should include weight loss (for those who are",
"      <span class=\"nowrap\">",
"       overweight/obese),",
"      </span>",
"      followed by ovulation induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      , or aromatase inhibitors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who are still anovulatory despite an adequate trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      or aromatase inhibitors, therapeutic options include ovulation induction with exogenous gonadotropins or laparoscopic surgery with electrocautery of laser. The evidence to date suggests that there are no significant differences in reproductive outcomes between laparoscopic surgery or gonadotropin therapy with the exception of multiple gestation rate, which is lower with laparoscopic surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other considerations include the need for careful monitoring with gonadotropin therapy, and possibly higher cost. However, there are potential risks and morbidity of laparoscopic surgery with general anesthesia, postoperative adhesion formation, and the theoretical risk of premature ovarian failure. Other important considerations when choosing between these two therapies include availability of local facilities and surgical expertise. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidates for laparoscopic surgery include women with PCOS who have failed an adequate trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (and possibly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      ), are non-obese (BMI &lt;30",
"      <span class=\"nowrap\">",
"       kg/m2),",
"      </span>",
"      and who have no other infertility factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Laparoscopic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In these women, the balance of risks and benefits for surgery versus gonadotropin therapy appears to be very close. Given the invasiveness of surgery, we suggest gonadotropin therapy for most women with PCOS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, women who prefer less monitoring and a lower risk of multiple gestations would reasonably choose surgery. Newer, less invasive techniques, such as transvaginal hydrolaparoscopy, may shift the balance toward surgery in the future. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Laparoscopic surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/1\">",
"      Amer SA, Li TC, Metwally M, et al. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod 2009; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/2\">",
"      Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril 1977; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/3\">",
"      Nunley, WC, Bateman, BG, Kitchen, JD. Reproductive performance of patients treated with clomiphene citrate. South Med J 1985; 78:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/4\">",
"      Wang CF, Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril 1980; 33:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/5\">",
"      Stein, IF, Leventhal, ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/6\">",
"      Portuondo JA, Melchor JC, Neyro JL, Alegre A. Periovarian adhesions following ovarian wedge resection or laparoscopic biopsy. Endoscopy 1984; 16:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/7\">",
"      Luciano AA. Laparotomy versus laparoscopy. Prog Clin Biol Res 1990; 358:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/8\">",
"      Luciano AA, Maier DB, Koch EI, et al. A comparative study of postoperative adhesions following laser surgery by laparoscopy versus laparotomy in the rabbit model. Obstet Gynecol 1989; 74:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/9\">",
"      Donesky BW, Adashi EY. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil Steril 1995; 63:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/10\">",
"      Farquhar CM, Williamson K, Gudex G, et al. A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2002; 78:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/11\">",
"      Bayram N, van Wely M, Kaaijk EM, et al. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004; 328:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/12\">",
"      Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P. Laparoscopic \"drilling\" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2005; :CD001122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/13\">",
"      Balen AH, Jacobs HS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994; 62:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/14\">",
"      G&uuml;rgan T, Urman B, Aksu T, et al. The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-YAG laser photocoagulation of polycystic ovaries. Obstet Gynecol 1992; 80:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/15\">",
"      Greenblatt E, Casper RF. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987; 156:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/16\">",
"      Lockwood GM, Muttukrishna S, Groome NP, et al. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 1998; 83:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/17\">",
"      Liguori G, Tolino A, Moccia G, et al. Laparoscopic ovarian treatment in infertile patients with polycystic ovarian syndrome (PCOS): endocrine changes and clinical outcome. Gynecol Endocrinol 1996; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/18\">",
"      Lemieux S, Lewis GF, Ben-Chetrit A, et al. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 1999; 84:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/19\">",
"      Seow KM, Juan CC, Hsu YP, et al. Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery. Hum Reprod 2007; 22:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/20\">",
"      Mio Y, Toda T, Tanikawa M, et al. Transvaginal ultrasound-guided follicular aspiration in the management of anovulatory infertility associated with polycystic ovaries. Fertil Steril 1991; 56:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/21\">",
"      Gj&ouml;nnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/22\">",
"      Daniell JF, Miller W. Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril 1989; 51:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/23\">",
"      Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 2000; 73:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/24\">",
"      Catenacci M, Goldberg JM. Transvaginal hydrolaparoscopy. Semin Reprod Med 2011; 29:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/25\">",
"      Flyckt RL, Goldberg JM. Laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Semin Reprod Med 2011; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/26\">",
"      Farquhar CM, Williamson K, Brown PM, Garland J. An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Hum Reprod 2004; 19:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/27\">",
"      Abdel Gadir A, Mowafi RS, Alnaser HM, et al. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin Endocrinol (Oxf) 1990; 33:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/28\">",
"      Gadir AA, Alnaser HM, Mowafi RS, Shaw RW. The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist. Fertil Steril 1992; 57:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/29\">",
"      Gj&oslash;nnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand 1994; 73:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/30\">",
"      Palomba S, Orio F Jr, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/31\">",
"      Palomba S, Falbo A, Battista L, et al. Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol 2010; 202:577.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/32\">",
"      Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/33\">",
"      Pirwany I, Tulandi T. Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? Fertil Steril 2003; 80:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/34\">",
"      Abdellah MS. Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2011; 113:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/35\">",
"      Gj&oslash;nnaess H. The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body-weight. Br J Obstet Gynaecol 1989; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/36\">",
"      Gj&ouml;nnaess H. A simple treatment for polycystic ovarian syndrome. World Health Forum 1990; 11:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/37\">",
"      Armar NA, McGarrigle HH, Honour J, et al. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 1990; 53:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/38\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/39\">",
"      G&uuml;rgan T, Ki��ni��&ccedil;i H, Yarali H, et al. Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease. Fertil Steril 1991; 56:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/40\">",
"      Greenblatt EM, Casper RF. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil Steril 1993; 60:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/41\">",
"      Dabirashrafi H. Complications of laparoscopic ovarian cauterization. Fertil Steril 1989; 52:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/42\">",
"      Melica F, Chiodi S, Cristoforoni PM, Ravera GB. Reductive surgery and ovarian function in the human--can reductive ovarian surgery in reproductive age negatively influence fertility and age at onset of menopause? Int J Fertil Menopausal Stud 1995; 40:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24583/abstract/43\">",
"      Elmashad AI. Impact of laparoscopic ovarian drilling on anti-M&uuml;llerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome. Fertil Steril 2011; 95:2342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3310 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24583=[""].join("\n");
var outline_f24_0_24583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LAPAROSCOPIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endocrine changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POTENTIAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/11/9404\" title=\"table 1\">",
"      Ovulation induction in PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24584="Trazodone: Drug information";
var content_f24_0_24584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trazodone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/44/34501?source=see_link\">",
"    see \"Trazodone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/744?source=see_link\">",
"    see \"Trazodone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10515304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oleptro&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trazodone D&reg;;",
"     </li>",
"     <li>",
"      Apo-Trazodone&reg;;",
"     </li>",
"     <li>",
"      Dom-Trazodone;",
"     </li>",
"     <li>",
"      Mylan-Trazodone;",
"     </li>",
"     <li>",
"      Novo-Trazodone;",
"     </li>",
"     <li>",
"      Nu-Trazodone;",
"     </li>",
"     <li>",
"      Nu-Trazodone D;",
"     </li>",
"     <li>",
"      Oleptro&trade;;",
"     </li>",
"     <li>",
"      PHL-Trazodone;",
"     </li>",
"     <li>",
"      PMS-Trazodone;",
"     </li>",
"     <li>",
"      ratio-Trazodone;",
"     </li>",
"     <li>",
"      Teva-Trazodone;",
"     </li>",
"     <li>",
"      Trazorel&reg;;",
"     </li>",
"     <li>",
"      ZYM-Trazodone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Serotonin Reuptake Inhibitor/Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 150 mg/day in 3 divided doses (may increase by 50 mg/day every 3-7 days); maximum dose: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release formulation: Initial: 150 mg once daily at bedtime (may increase by 75 mg/day every 3 days); maximum dose: 375 mg/day; once adequate response obtained, gradually reduce with adjustment based on therapeutic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic effects may take up to 6 weeks. Therapy is normally maintained for 6-12 months after optimum response is reached to prevent recurrence of depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation/hypnotic (unlabeled use):",
"     </b>",
"     Oral: 25-50 mg at bedtime (often in combination with daytime SSRIs). May increase up to 200 mg at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of trazodone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing trazodone and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate trazodone in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving trazodone and potential benefits outweigh potential risks, discontinue trazodone  promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume trazodone 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F230299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/744?source=see_link\">",
"      see \"Trazodone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 6-12 years:",
"     </i>",
"     Initial: 1.5-2 mg/kg/day in divided doses; increase gradually every 3-4 days as needed; maximum: 6 mg/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents:",
"     </i>",
"     Initial: 25-50 mg/day; increase to 100-150 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Oral: 25-50 mg at bedtime with 25-50 mg/day dose increase every 3 days for inpatients and weekly for outpatients, if tolerated; usual dose: 75-150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Refer to adult dosing. Use with caution in the elderly; clinical experience is limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg, 100 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oleptro&trade;: 150 mg, 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9837787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oleptro&trade; extended release tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM202202.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM202202.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Trazodone tablets:",
"     <a href=\"file://dailymed.nlm.nih.gov/dailymed/medguide.cfm?id=37846\" target=\"_blank\">",
"      file://dailymed.nlm.nih.gov/dailymed/medguide.cfm?id=37846",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet: Dosing after meals may decrease lightheadedness and postural hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: Take on an empty stomach; swallow whole or as a half tablet without food. Tablet may be broken along the score line, but do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F230313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential augmenting agent for antidepressants, hypnotic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Desyrel may be confused with deferoxamine, Demerol&reg;, Delsym&reg;, Zestril&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TraZODone may be confused with traMADol, ziprasidone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Desyrel [Canada, Turkey] may be confused with Deseril brand name for methysergide [Australia, Belgium, Great Britain, Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sedation (&le;46%), headache (10% to 33%), dizziness (20% to 28%), fatigue (6% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (15% to 34%), nausea (10% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 7%), hypotension (&le;7%), syncope (&le;5%), hypertension (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion (5% to 6%), incoordination (2% to 5%), concentration decreased (1% to 3%), disorientation (&le;2%), memory impairment (&le;1%), agitation, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 9%), constipation (7% to 8%), abdominal pain, abnormal taste, flatulence, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculation disorder (2%), urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (&le;5%), tremor (1% to 5%), paresthesia (&le;1%), myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (3% to 6%), dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Night sweats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreams, abnormal orgasm, acne, akathisia, allergic reactions, alopecia, amylase increased, anemia, anxiety, aphasia, apnea, appetite increased, arrhythmia, ataxia, atrial fibrillation, bladder pain, bradycardia, breast enlargement/engorgement, cardiac arrest, cardiospasm, cerebrovascular accident, chest pain, CHF, chills, cholestasis, clitorism, conduction block, diplopia, early menses, erectile dysfunction, extrapyramidal symptoms, eye pain, flushing, gait disturbance, hallucination, hearing loss (partial), hematuria, hemolytic anemia, hepatitis, hirsutism, hyperbilirubinemia, hyperhidrosis, hypersalivation, hypersensitivity, hypoesthesia, hypomania, impaired speech, impotence,  insomnia, jaundice, lactation, leukocytosis, leukonychia, libido increased, liver enzyme alteration, methemoglobinemia, MI, muscle twitching, orthostatic hypotension, palpitation, paranoia, photophobia, photosensitivity reaction, priapism, pruritus, psoriasis, psychosis, QT prolongation, rash, reflux esophagitis, retrograde ejaculation, salivation increased, seizure, SIADH, speech impairment, stupor, tachycardia, tardive dyskinesia, tinnitus, torsade de pointes, urinary frequency increased, urinary retention, urinary incontinence, urticaria, vasodilation, ventricular ectopy, ventricular tachycardia, vertigo, dry eyes, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trazodone or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or  within 14 days of discontinuing either trazodone or the MAO inhibitor); initiation of trazodone in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years of age. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Trazodone is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: Drugs that interfere with serotonin reuptake (eg, SSRIs) have been associated with bleeding ranging from relatively minor bruising and epistaxis to life-threatening hemorrhage; similar to these agents, trazodone may also impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause orthostatic hypotension and syncope (risk is high relative to other antidepressants); use with caution in patients at risk of these effects or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Painful erection &gt;6 hours in duration; rare. Instruct patient to seek medical assistance for erection lasting &gt;4 hours. Use with caution in patients who have conditions which may predispose them to priapism (eg, sickle cell anemia, multiple myeloma, leukemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation/proarrhythmia: Although the risk of conduction abnormalities is low relative to other antidepressants, QT prolongation (with or without torsade de pointes) and ventricular tachycardia has been observed with the use of trazodone (reports limited to immediate-release formulation); use with caution in patients with pre-existing cardiac disease. Other arrhythmias reported include isolated PVCs, ventricular couplets, and tachycardia with syncope. Concurrent use of CYP3A4 inhibitors may increase the risk of QT prolongation and/or proarrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: Some antidepressant agents (eg, SSRIs) have been associated with the development of SIADH; hyponatremia has been reported (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is low relative to other antidepressants. Not recommended for use in a patient during the acute recovery phase of MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Trazodone is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods; gradually reduce dosage prior to complete discontinuation to avoid withdrawal symptoms (eg, anxiety, agitation, sleep disturbance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with darunavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: TraZODone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the QTc-prolonging effect of TraZODone. Saquinavir may increase the serum concentration of TraZODone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of TraZODone. Management: Consider using a lower dose of trazodone when used in combination with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: TraZODone may diminish the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F230277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Time to peak serum levels may be increased if immediate release trazodone is taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in some animal reproduction studies. When trazodone is taken during pregnancy, an increased risk of major malformations has not been observed in the limited number of pregnancies studied (Einarson, 2003; Einarson, 2009). The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     trazodone exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with antidepressants during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. Consideration should be given to using agents with safety data in pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (ACOG, 2008; APA, 2010; Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5634584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trazodone is excreted into breast milk; breast milk concentrations peak ~2 hours following administration. It is not known if the trazodone metabolite is found in breast milk (Verbeeck, 1986). The long-term effects on neurobehavior have not been studied. The manufacturer recommends that caution be exercised when administering trazodone to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Oleptro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $115.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $140.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TraZODone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $56.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $73.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $146.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $543.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4794638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline liver function prior to and periodically during therapy; suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); signs/symptoms of serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F230260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plasma levels do not always correlate with clinical effectiveness",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 0.5-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;4 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azonz (FI);",
"     </li>",
"     <li>",
"      Deprax (ES);",
"     </li>",
"     <li>",
"      Deprel (PK);",
"     </li>",
"     <li>",
"      Depresil (PH);",
"     </li>",
"     <li>",
"      Desirel (TH);",
"     </li>",
"     <li>",
"      Desyrel (JP);",
"     </li>",
"     <li>",
"      Devidon (HR);",
"     </li>",
"     <li>",
"      Donaren (BR);",
"     </li>",
"     <li>",
"      Mesyrel (CL);",
"     </li>",
"     <li>",
"      Molipaxin (GB, IE);",
"     </li>",
"     <li>",
"      Pragmarel (FR);",
"     </li>",
"     <li>",
"      Reslin (JP);",
"     </li>",
"     <li>",
"      Taxagon (AR);",
"     </li>",
"     <li>",
"      Taxagon AC (UY);",
"     </li>",
"     <li>",
"      Tazodac (IN);",
"     </li>",
"     <li>",
"      Thombran (DE);",
"     </li>",
"     <li>",
"      Trazo (TH);",
"     </li>",
"     <li>",
"      Trazodil (IL);",
"     </li>",
"     <li>",
"      Trazodone-Continental (LU);",
"     </li>",
"     <li>",
"      Trazolan (BE, IN, LU, NL);",
"     </li>",
"     <li>",
"      Trazone (PT, TW);",
"     </li>",
"     <li>",
"      Trazonil (IN);",
"     </li>",
"     <li>",
"      Trittico (AE, AT, BG, BH, CH, CN, CO, CY, EG, GR, HK, HN, IL, IQ, IR, IT, JO, KP, KW, LB, LY, OM, PE, PL, PY, QA, RU, SA, SG, SY, VE, YE);",
"     </li>",
"     <li>",
"      Trittico AC (CN, CO, CZ);",
"     </li>",
"     <li>",
"      Trittico CR (KP);",
"     </li>",
"     <li>",
"      Trittico Prolonged-Release (HK);",
"     </li>",
"     <li>",
"      Zodonrel (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits reuptake of serotonin, causes adrenoreceptor subsensitivity, and induces significant changes in 5-HT presynaptic receptor adrenoreceptors. Trazodone also significantly blocks histamine (H",
"     <sub>",
"      1",
"     </sub>",
"     ) and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic (antidepressant): Up to 6 weeks; sleep aid: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; Extended release: C",
"     <sub>",
"      max",
"     </sub>",
"     increases ~86% when taken shortly after ingestion of a high-fat meal compared to fasting conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (extensive) to an active metabolite (mCPP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 30-100 minutes; delayed with food (up to 2.5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 9 hours; not significantly affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (&lt;1% excreted unchanged); secondarily feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Psychiatric Association, \"Treatment Recommendations for Patients With Major Depressive Disorder,\" 3rd ed, May 2010. Available at file://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Battistella PA, Ruffilli R, Cernetti R, et al, &ldquo;A Placebo-Controlled Crossover Trial Using Trazodone in Pediatric Migraine,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1993, 33(1):36-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/8436497/pubmed\" id=\"8436497\" target=\"_blank\">",
"        8436497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bayer AJ, Pathy MSJ, and Ankier SI, &ldquo;Pharmacokinetic and Pharmacodynamic Characteristics of Trazodone in the Elderly,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1983, 16:371-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/6626432/pubmed\" id=\"6626432\" target=\"_blank\">",
"        6626432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Choi J, Einarson TR, et al, \"Incidence of Major Malformations in Infants Following Antidepressant Exposure in Pregnancy: Results of a large Prospective Cohort Study,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2009, 54(4):242-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/19321030/pubmed\" id=\"19321030\" target=\"_blank\">",
"        19321030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fishbain DA, &ldquo;Re: Priapism Associated With Trazodone Therapy,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 1989, 142(3):831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/2769875/pubmed\" id=\"2769875\" target=\"_blank\">",
"        2769875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerson SC, Plotkin DA, and Jarvik LF, &ldquo;Antidepressant Drug Studies, 1964-1986: Empirical Evidence for Aging Patients,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1988, 8(5):311-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/3053796/pubmed\" id=\"3053796\" target=\"_blank\">",
"        3053796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klier CM, Mossaheb N, Saria A, et al, \"Pharmacokinetics and Elimination of Quetiapine, Venlafaxine, and Trazodone During Pregnancy and Postpartum,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2007, 27(6):720-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/18004149/pubmed\" id=\"18004149\" target=\"_blank\">",
"        18004149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, Ades J, and Rouillon F, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2(2):132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesar T, Kingston R, Dahms R, et al, &ldquo;Trazodone Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1982, 12(4):221-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/6838028/pubmed\" id=\"6838028\" target=\"_blank\">",
"        6838028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeves RR and Bullen JA, &ldquo;Serotonin Syndrome Produced by Paroxetine and Low-Dose Trazodone,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 1995, 36(2):159-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/7724720/pubmed\" id=\"7724720\" target=\"_blank\">",
"        7724720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberge RJ, Luellen JR, and Reed, S, &ldquo;False-Positive Amphetamine Screen Following a Trazodone Overdose,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2001, 39(2):181-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/11407508/pubmed\" id=\"11407508\" target=\"_blank\">",
"        11407508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, Ross SG, and McKenna EA, \"Excretion of Trazodone in Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1986, 22(3):367-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/3768252/pubmed\" id=\"3768252\" target=\"_blank\">",
"        3768252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zmitek A, &ldquo;Trazodone-Induced Mania,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1987, 151:274-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/3690130/pubmed\" id=\"3690130\" target=\"_blank\">",
"        3690130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zubieta JK and Alessi NE, &ldquo;Acute and Chronic Administration of Trazodone in the Treatment of Disruptive Behavior Disorders in Children,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1992, 12(5):346-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/0/24584/abstract-text/1479052/pubmed\" id=\"1479052\" target=\"_blank\">",
"        1479052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10013 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24584=[""].join("\n");
var outline_f24_0_24584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708898\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10515304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230281\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230317\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230284\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230299\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230285\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230259\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230245\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837787\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230264\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230263\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230313\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230325\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230315\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230267\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230249\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230311\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230254\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230277\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230255\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722230\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230289\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5634584\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230269\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4794638\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230260\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038849\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230248\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230266\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/44/34501?source=related_link\">",
"      Trazodone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/744?source=related_link\">",
"      Trazodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24585="Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins";
var content_f24_0_24585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24585/contributors\">",
"     David J Roberts, MA, MB, D. Phil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24585/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/0/24585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most red cell genetic defects in human populations (eg, thalassemia, G6PD deficiency, sickle cell anemia) appear to be due to the exposure to malaria, a disease estimated to have arisen about 3000 years ago with the emergence of agriculture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Humans exhibit variable susceptibility to malarial infection; most of the resistance to this infection is either genetic, environmental, based upon previous exposure, or access to therapy.",
"   </p>",
"   <p>",
"    A study of the relative importance of each of these factors to the overall burden of malarial disease in human populations was examined in Sri Lanka. Longitudinal studies showed that 20 percent of the variation in the intensity of disease was explained by repeatable differences between patients and approximately half was attributable to host genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/4\">",
"     4",
"    </a>",
"    ]. A similar analysis in Africa demonstrated 25 percent of the total variation in the incidence of hospital admission for malaria was explained by additively-acting host genes, with 2 percent of this variation due to presence of the sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of certain blood group antigens in malarial infection and genetic resistance to malaria associated with abnormalities in the red cell cytoskeleton will be reviewed here. The overall subject of anemia in malaria, as well as malarial resistance associated with the hemoglobinopathies (eg, hemoglobins S, C, E, thalassemia), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=see_link\">",
"     \"Anemia in malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmodium falciparum malaria, the deadly form of malaria, has a life cycle that includes a sexual cycle in an Anopheles mosquito and a human cycle that includes a liver stage and an obligatory erythrocytic stage. Genetic resistance is much better defined for the erythrocytic stage and may involve one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibition of merozoite entry into the red cell",
"     </li>",
"     <li>",
"      Impairment of intracellular parasite growth",
"     </li>",
"     <li>",
"      Prevention of the erythrocyte lysis that occurs with parasite maturation, leading to release of merozoites into the bloodstream",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malarial invasion of the red cell is a complex process, involving initial nonspecific attachment, reorientation of the polarity of the merozoite, red cell membrane flapping, and the zipper-type introjection of the merozoite into the red cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/6\">",
"     6",
"    </a>",
"    ]. It is therefore not surprising that mutations involving the red cell membrane (eg, surface antigens and cytoskeletal proteins) could interfere with such invasion.",
"   </p>",
"   <p>",
"    As will be described below, malarial invasion of the red cells requires both red cell receptors, such as the Duffy blood group antigen for P. vivax and glycophorin A for P. falciparum, and parasite proteins that bind to the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RED CELL SURFACE ANTIGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell surface antigens can affect the likelihood of developing malaria. The best described are the Duffy blood group determinants and the glycophorins, although there is increasing evidence for the role of the ABO blood group system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duffy blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Duffy blood group system is polymorphic and includes five alloantigens, two of which are codominant alleles (Fya and Fyb) that differ by a change at nucleotide 306: guanine in Fya and adenine in Fyb [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/10\">",
"     10",
"    </a>",
"    ]. Both Fya and Fyb reside in a glycoprotein of about 40 kD, known as the Duffy antigen receptor for chemokines (DARC, CD234), which acts as a receptor for certain pro-inflammatory cytokines (eg, IL-8, monocyte chemotactic protein-1, RANTES) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H45#H45\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duffy antigen negativity corresponds to a null genotype in which neither the Fya nor Fyb antigen (Fy(a-b-)) is expressed. Most Duffy-negative people of African descent have a silent Fyb allele with a single nucleotide substitution that impairs promoter activity in erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/13\">",
"     13",
"    </a>",
"    ]. The percent of the population with the Fy(a-b-) phenotype reaches 100 percent in much of Sub-Saharan Africa. It seems that its selective advantage (ie, resistance to invasion by the merozoites of P. vivax) has driven this phenotype nearly to fixation. In Gambian individuals, for example, 100 percent are Duffy negative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/14\">",
"     14",
"    </a>",
"    ]. This trait is also found in Arabs, Oriental Jews, the Druzes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/15\">",
"     15",
"    </a>",
"    ], and in Papua New Guinea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fy(a-b-) erythrocytes were first shown to be resistant to invasion by the merozoites of P. knowlesi, a Plasmodium similar to P. vivax that normally infects monkeys [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/17\">",
"     17",
"    </a>",
"    ]. The importance of the Duffy blood group system in P. vivax infection in man has been shown in several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 1958 study performed before in vitro malaria cultures were available, human volunteers were exposed to mosquitoes infected with P. vivax [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/18\">",
"       18",
"      </a>",
"      ]. Duffy-negative individuals were resistant to infection, while control subjects fell sick with malaria 11 to 15 days after exposure.",
"     </li>",
"     <li>",
"      The crucial role of the Duffy blood group antigen for erythrocyte invasion was obtained in epidemiologic studies of soldiers suffering from P. vivax infection acquired in Vietnam [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/19\">",
"       19",
"      </a>",
"      ] and in children with malaria in Papua New Guinea [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using a short-term in vitro culture system, antibodies directed against a new Duffy determinant, Fy6, blocked invasion of erythrocytes by P. vivax as effectively as antibodies directed against the intact molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Duffy blood group antigen is a receptor for IL-8 and melanoma growth stimulatory activity (MGSA); invasion of P. knowlesi blood stage merozoites into erythrocytes carrying the Duffy antigen can be inhibited by MGSA and IL-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/21\">",
"       21",
"      </a>",
"      ]. Subsequent studies narrowed the binding site on the Duffy antigen to a 35 amino acid region [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      P. vivax infections have been reported as not infrequent occurrences in Duffy-negative individuals in Madagascar [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/23\">",
"       23",
"      </a>",
"      ]. The extent of this phenomenon in the rest of sub-Saharan Africa is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Parasite proteins that bind to Duffy antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;One protein from P. vivax and three proteins from the simian malarial organism P. knowlesi have been described that bind to the Duffy blood group antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/24\">",
"     24",
"    </a>",
"    ]. These proteins shared sequence homology and a cysteine-rich domain was found within P. vivax Duffy Binding Ligand which mediated adhesion to Duffy blood group-positive but not Duffy blood group-negative human erythrocytes. The homologous domain of the proteins from P. knowlesi also bound erythrocytes but had different specificities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The erythrocyte binding domains in these proteins, namely the Duffy binding domains, also showed sequence conservation with the domain for erythrocyte binding in the P. falciparum protein, erythrocyte-binding antigen-175, which bound to sialic acid on human erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The conservation of this binding domain between distant malarial species strongly suggested that these structures were functionally significant and might therefore be potential vaccine candidates.",
"   </p>",
"   <p>",
"    These suggestions were confirmed by hyper-variability of the erythrocyte-binding domain in the P. vivax Duffy binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/25\">",
"     25",
"    </a>",
"    ]. The binding domains within these erythrocyte-binding proteins (PvDBPs) lie within a conserved N-terminal cysteine-rich region of 330 amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/26\">",
"     26",
"    </a>",
"    ]. Recombinant proteins have been developed that stimulate blocking antibodies and block erythrocyte invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/27\">",
"     27",
"    </a>",
"    ]. These proteins are now leading candidates for a vaccine blocking red cell invasion of the malarial parasite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glycophorin A and other surface antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malarial parasites use several receptors on the surface of erythrocytes during invasion and during the rosetting of unaffected erythrocytes by infected erythrocytes. However, epidemiologic and laboratory evidence for significant protection against falciparum malaria by blood group polymorphisms is limited and somewhat inconsistent.",
"   </p>",
"   <p>",
"    The capacity of malarial parasites to invade cells with modified O-linked saccharides is reduced. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of sialic acid (N-acetyl neuraminic acid) from the red cell surface reduces invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/28-31\">",
"       28-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tn+ erythrocytes (constitutively deficient in sialic acid and galactose in O-linked oligosaccharides) and Cad+ erythrocytes (with an extra N-acetyl galactosamine residue next to sialic acid residues) are resistant to invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is no evidence that the blood groups Tn+, Cad+ or En- (sialic acid deficient) or other variants of glycophorin A reach polymorphic frequencies in those living in endemic areas for malaria. This is somewhat puzzling as a malarial ligand for glycophorin A has been identified (EBA-175) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/9\">",
"     9",
"    </a>",
"    ] and monoclonal antibodies to glycophorin A inhibit invasion of P. falciparum and P. knowlesi in vitro, while antibodies against glycophorin B, Rh, and Kell determinants have no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the malarial parasite uses alternate invasion pathways, thus minimizing any selective advantage of mutation in glycophorin A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     ABO(H) blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have suggested that group A red cells are associated with severe malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] while two additional studies, including a large study of 9000 children, have shown conclusively that blood group O confers protection (odds Ratio 1.2; 95% CI 1.09-1.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These observations are consistent with the low frequency of blood group A in many endemic malarial areas. Possible mechanisms for such a protective effect include the modulation of rosetting of uninfected red blood cells by infected red blood cells as well as the adherence of infected red blood cells to host receptors on monocytes, platelets, and endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/39\">",
"     39",
"    </a>",
"    ]. This effect has been exhibited by some P. falciparum strains via the ABO(H) group of red blood cells ex vivo and ABO(H) blood group substances in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical evidence from Thailand and East Africa has supported the role for the influence of rosetting by ABO blood group type. In these studies the frequency of rosetting parasites was less in blood isolated from Group O patients than from patients with Groups A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/42\">",
"     42",
"    </a>",
"    ] or A and AB [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The association of blood group O with protection and with reduced rosetting has also been confirmed in a large case control study of malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ABO(H) blood group polymorphisms also modulate sialic acid recognition by some pathogen receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/46\">",
"     46",
"    </a>",
"    ], and may alter the rate of phagocytosis of infected red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/47\">",
"     47",
"    </a>",
"    ]; it remains unclear if these phenomena are mechanisms of protection in malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glycophorin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is experimental evidence that S-s-U- cells deficient in glycophorin B are relatively resistant to malarial invasion. It has been suggested that P. falciparum contains at least two receptors, each of which binds to different ligands on glycophorin B, and that different strains may differ in the quantity or affinity of these receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, invasion of two different malarial strains was evaluated in erythrocytes that lack glycophorins A and B; the efficiency of invasion was 20 and 50 percent of normal, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/48\">",
"     48",
"    </a>",
"    ]. Nevertheless, the blood group S-s-U- is found in 2 to 5 percent of Africans, suggesting malaria may have provided a selective force for this polymorphism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/50\">",
"     50",
"    </a>",
"    ]. The parasite ligand for glycophorin B has been identified as the P. falciparum Erythrocyte Binding Ligand &ndash; 1 (EBL-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glycophorin C and the Gerbich antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A parasite receptor has been identified for the polymorphic glycophorin C that determines the Gerbich (Ge) blood group system. Deletion of exon 3 in the glycophorin C gene reaches a high frequency (46.5 percent) in coastal areas of Papua New Guinea where malaria is hyperendemic. The receptor for P. falciparum erythrocyte-binding antigen 140 (EBA140, BAEBL) is glycophorin C; this interaction mediates a principal P. falciparum invasion pathway into human erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/52\">",
"     52",
"    </a>",
"    ]. BAEBL is one of four P. falciparum invasion proteins with Duffy-binding like domains (DBLs) and the BAEBL allele containing threonine at position 121 (T121) (VSTK) can bind to glycophorin C [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other reports, a normal protein",
"    <span class=\"nowrap\">",
"     4.1/glycophorin",
"    </span>",
"    <span class=\"nowrap\">",
"     C/p55",
"    </span>",
"    complex appears to be important for P. falciparum invasion and development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. The 4.1 protein is also involved in the binding to the red cell cytoskeleton of P. falciparum erythrocyte membrane protein-1 (PfEMP1), a protein involved in adhesion of malaria-infected red cells to the vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hereditary elliptocytosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a survey of 266 Melanesian individuals, the prevalence of P. falciparum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    P. vivax infection was significantly lower in Gerbich-negative compared with Gerbich-positive subjects (5.7 versus 18.6 percent), while P. malariae occurred at comparable rates of about 8 percent in Gerbich-negative and Gerbich-positive subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/59\">",
"     59",
"    </a>",
"    ]. However, other studies have not shown that glycophorin C deficiency is associated with differences in either P. falciparum or P vivax infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/60\">",
"     60",
"    </a>",
"    ]. While these findings suggest that Ge negativity has arisen in Melanesian populations through natural selection by reducing severe malaria, confirmation by further case-control studies is awaited with interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complement receptor type 1 and Knops blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement receptor type 1 (CR1) has been implicated in rosetting of uninfected red blood cells to Plasmodium falciparum-infected cells, a phenomenon which is associated with severe malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/61\">",
"     61",
"    </a>",
"    ]. CR1 has also been identified as the sialic acid-independent receptor used by parasites during the invasion of red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/62\">",
"     62",
"    </a>",
"    ]. The Plasmodium&nbsp;falciparum&nbsp;adhesin PfRh4 binds to complement receptor type-1 (CR1) at the complement control protein modules 1 to 3 (CCP1-3) at the membrane-distal amino terminus of&nbsp;CR1 that also bind to C4b and C3b [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Knops blood group (KN) is located on CR1 and two of these antigens [ie, McCoy (McC) and Swain-Langley (Sl(a))], have been associated with mutations of CR1, and show marked frequency differences between Caucasians and Africans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/64\">",
"     64",
"    </a>",
"    ]. The African alleles Sl(2) and McC(b) of CR1 may confer a survival advantage in the setting of P. falciparum malaria. As an example, children with the",
"    <span class=\"nowrap\">",
"     Sl(2/2)",
"    </span>",
"    genotype were less likely to have cerebral malaria (OR 0.17; 95% CI 0.04-0.72) than children with",
"    <span class=\"nowrap\">",
"     Sl(1/1)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/65\">",
"     65",
"    </a>",
"    ]. The role of CR1 phenotypes in protection from malaria in other populations is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347495001\">",
"    <span class=\"h2\">",
"     Basigin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ok blood group antigen, basigin, has been identified as a receptor for PfRh5, a parasite ligand that is essential for blood stage growth. Erythrocyte invasion was inhibited by soluble basigin or by basigin knockdown, and invasion could be completely blocked using low concentrations of anti-basigin antibodies across all laboratory strains. Furthermore, Ok(a-) erythrocytes, which express a basigin variant that has a weaker binding affinity for PfRh5, had reduced invasion efficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/66\">",
"     66",
"    </a>",
"    ]. However, it is puzzling that Ok blood group antigens are not obviously polymorphic in malaria endemic regions. Nevertheless, these findings have provoked renewed interest in PfRh5 as a good vaccine candidate antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RED CELLS WITH CYTOSKELETAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the complexity of malarial invasion of the red cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/6\">",
"     6",
"    </a>",
"    ], it is not surprising that mutations in cytoskeletal proteins could lead to red cell resistance to P. falciparum. Protection against malaria has been associated with three genetic disorders involving the red cell cytoskeleton: Southeast Asian ovalocytosis, hereditary elliptocytosis, and hereditary spherocytosis. A discussion of the functions of the different cytoskeletal proteins can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Southeast Asian ovalocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Southeast Asian or Melanesian ovalocytosis (SAO), the sole highly polymorphic red cell cytoskeleton abnormality, is present in about 30 percent of the Melanesian population of Papua New Guinea and other aboriginal populations of Southeast Asia. It results from mutations in band 3 protein, which primarily functions as a chloride-bicarbonate exchanger. The net effect of this mutation is a red cell with increased rigidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Band 3 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiologic evidence suggests that SAO confers resistance to high levels of parasitemia with P. falciparum, P. vivax, and P. malariae [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. It may also protect against cerebral malaria in patients infected with P. falciparum. In one study of inhabitants of the Madang area of Papua New Guinea, for example, heterozygous SAO was present in 15 percent of all inhabitants, 9 percent of those who had uncomplicated P. falciparum malaria, and in none of those with potentially life-threatening cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the prevalence of ovalocytosis did not differ between children with and without acute P. falciparum malaria, suggesting that ovalocytosis protects from dying of malaria but not from acquiring malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations are consistent with in vitro studies. Melanesian ovalocytes are highly resistant to invasion by P. falciparum merozoites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. They are also resistant to invasion by P. knowlesi, a plasmodium similar to P. vivax [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/72\">",
"     72",
"    </a>",
"    ]. Interestingly, a similar defect in P. knowlesi invasion can be induced in normal erythrocytes by monoclonal antibodies directed against band 3, the protein that is abnormal in SAO [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why merozoites are unable to invade the ovalocytic cell is not well understood. Inhibition of invasion of two types of plasmodia suggests involvement of a later stage of invasion than receptor recognition. In vitro studies suggest that it is decreased deformability, not the ovalocytic shape per se, that is of primary importance in protecting against malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/73\">",
"     73",
"    </a>",
"    ] and that the degree of impaired invasion is closely related to the degree of reduced deformability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an additional aspect to this relationship, since malaria infection also induces the generation of ovalocytes. In one series from Thailand, individuals infected with malaria had a higher percent of ovalocytes than uninfected controls (6.3 percent with P. falciparum, 8.3 percent with P. vivax, and 0.6 percent in uninfected controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/76\">",
"     76",
"    </a>",
"    ]. Infected ovalocytes contained significantly fewer parasites than infected discocytes, suggesting that the development of ovalocytes could represent a host response to parasite multiplication within the circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hereditary elliptocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary elliptocytosis (HE) is a disorder of the red cell cytoskeleton, in which mutations in protein 4.1, alpha spectrin, beta spectrin, band 3, and glycophorin C have been described. HE red cells demonstrate resistance to invasion by both P. knowlesi and P. falciparum. Indirect evidence for protection against clinical disease comes from the observation that HE is found in high prevalence in regions in which malaria has been or is endemic. As an example, the prevalence of HE in the United States is 2.5 to 5 per 10,000 but may be greater than 1 to 10 percent in areas in which malaria is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The resistance of HE cells to malarial infection may involve diminished invasion, poor intraerythrocytic growth, or diminished cytoadherence of infected erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/80\">",
"     80",
"    </a>",
"    ]. In particular, a normal protein",
"    <span class=\"nowrap\">",
"     4.1/glycophorin",
"    </span>",
"    <span class=\"nowrap\">",
"     C/p55",
"    </span>",
"    complex appears to be important for parasite invasion and development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/55\">",
"     55",
"    </a>",
"    ]. A review of the functions of the different cytoskeletal proteins can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relevance of this protein complex for successful multiplication of the parasite is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      P. falciparum invasion into protein 4.1-deficient or glycophorin C-deficient red cells is greatly reduced; once inside, parasites grow normally in the latter cells but poorly in the former [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/55\">",
"       55",
"      </a>",
"      ]. Since the p55 protein is deficient in both types of abnormal red cells, p55 may be important for cell invasion but not for parasite growth.",
"     </li>",
"     <li>",
"      P. falciparum parasites that generate mature-parasite-infected erythrocyte surface antigen (MESA), a protein that is thought to play a role in regulating cytoadherence, do not grow well in protein 4.1-deficient red cells. MESA binds to protein 4.1 in normal RBCs and the failure of this association in the cytoplasm of 4.1-deficient cells probably explains the accumulation of large amounts of MESA, an event that is presumably unfavorable for parasite development [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common structural variants that increase the content of spectrin dimers also exhibit impaired parasite growth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/81\">",
"     81",
"    </a>",
"    ]. This pattern is distinct from that seen in hereditary spherocytosis, in which parasite growth is diminished in proportion to the reduction in spectrin content (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Hereditary spherocytosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an additional aspect to the relationship between protein 4.1 and P. falciparum. Red cell membrane proteins may become modified during intracellular growth of P. falciparum. One example is an 80 kD phosphoprotein associated with the red cell membrane of P. falciparum-infected cells. This protein appears to be a phosphorylated form of protein 4.1, since it is not seen in infected HE cells that are completely devoid of protein 4.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/82\">",
"     82",
"    </a>",
"    ]. The possible role of this phosphoprotein in parasite growth and survival is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hereditary spherocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) is a result of heterogeneous alterations in one of five genes that encode for proteins involved in vertical associations which tie the membrane skeleton to the lipid bilayer. HS has not been reported at polymorphic frequencies in any region of the world and its role in protection against malaria is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an in vitro study, P. falciparum growth in HS erythrocytes showed a unique pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/81\">",
"     81",
"    </a>",
"    ]. Growth was normal during the first two days, followed by impaired growth, the onset of which was more rapid in cells with greater degrees of spectrin deficiency. In other experiments in",
"    <span class=\"nowrap\">",
"     ankyrin/spectrin",
"    </span>",
"    deficient mice, spectrin appeared to be necessary for the invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth of malarial parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/83\">",
"     83",
"    </a>",
"    ]. Heterozygous ankyrin-1 null mice have wild-type levels of ankyrin-1 and spectrin with normal red cell survival but are nevertheless protected from malaria. Resistance is not due to reduced invasion; the exact mechanism of protection is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations in HE and HS suggest that skeletal membrane proteins may play a role in both parasite invasion and growth, according to the defect that is present. One possible mechanism by which parasite growth is impaired, as mentioned above, is accumulation of MESA in protein 4.1-deficient cells. Other possibilities include involvement of host cytoskeletal proteins in the generation of the parasite membrane or the insertion of parasite proteins into the red cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parasitization with P. falciparum also induces a loss of red cell deformability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24585/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. This effect is more prominent in more mature forms (trophozoites and schizonts) and may affect the likelihood of microvascular occlusion (and therefore the ischemic complications of severe falciparum malaria) as well as the clearance of parasitized cells by the reticuloendothelial system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15309759\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malarial invasion of the red cell is a complex process. Mutations involving the red cell membrane (eg, surface antigens and cytoskeletal proteins) interfere with such invasion, and offer protection against malaria. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanisms of protection'",
"    </a>",
"    above.) Surface antigens that offer protection include (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Red cell surface antigens'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duffy blood group system",
"     </li>",
"     <li>",
"      ABO(H) blood group system",
"     </li>",
"     <li>",
"      Glycophorins",
"     </li>",
"     <li>",
"      Gerbich antigen",
"     </li>",
"     <li>",
"      Complement receptor type 1",
"     </li>",
"     <li>",
"      Knops blood group",
"     </li>",
"     <li>",
"      Basigin &ndash; Ok blood group",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormalities of the red cell cytoskeleton which may offer protection include (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Red cells with cytoskeletal abnormalities'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Southeast Asian ovalocytosis",
"     </li>",
"     <li>",
"      Hereditary elliptocytosis",
"     </li>",
"     <li>",
"      Hereditary spherocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inherited abnormalities of hemoglobin that may offer protection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/1\">",
"      Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/2\">",
"      Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985; 230:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/3\">",
"      Ohashi J, Naka I, Patarapotikul J, et al. Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection. Am J Hum Genet 2004; 74:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/4\">",
"      Mackinnon MJ, Gunawardena DM, Rajakaruna J, et al. Quantifying genetic and nongenetic contributions to malarial infection in a Sri Lankan population. Proc Natl Acad Sci U S A 2000; 97:12661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/5\">",
"      Mackinnon MJ, Mwangi TW, Snow RW, et al. Heritability of malaria in Africa. PLoS Med 2005; 2:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/6\">",
"      Miller LH, Aikawa M, Johnson JG, Shiroishi T. Interaction between cytochalasin B-treated malarial parasites and erythrocytes. Attachment and junction formation. J Exp Med 1979; 149:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/7\">",
"      Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994; 180:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/8\">",
"      Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1992; 89:7085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/9\">",
"      Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/10\">",
"      Chaudhuri A, Polyakova J, Zbrzezna V, Pogo AO. The coding sequence of Duffy blood group gene in humans and simians: restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in Duffy-negative individuals. Blood 1995; 85:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/11\">",
"      Hadley TJ, David PH, McGinniss MH, Miller LH. Identification of an erythrocyte component carrying the Duffy blood group Fya antigen. Science 1984; 223:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/12\">",
"      Chaudhuri A, Zbrzezna V, Johnson C, et al. Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for Plasmodium vivax and Plasmodium knowlesi malaria parasite. J Biol Chem 1989; 264:13770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/13\">",
"      Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995; 10:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/14\">",
"      Welch SG, McGregor IA, Williams K. The Duffy blood group and malaria prevalence in Gambian West Africans. Trans R Soc Trop Med Hyg 1977; 71:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/15\">",
"      Sandler SG, Kravitz C, Sharon R, et al. The Duffy blood group system in Israeli Jews and Arabs. Vox Sang 1979; 37:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/16\">",
"      Zimmerman PA, Woolley I, Masinde GL, et al. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad Sci U S A 1999; 96:13973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/17\">",
"      Miller LH, Mason SJ, Dvorak JA, et al. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 1975; 189:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/18\">",
"      YOUNG MD, EYLES DE, BURGESS RW, JEFFERY GM. Experimental testing of the immunity of Negroes to Plasmodium vivax. J Parasitol 1955; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/19\">",
"      Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/20\">",
"      Barnwell JW, Nichols ME, Rubinstein P. In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax. J Exp Med 1989; 169:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/21\">",
"      Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993; 261:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/22\">",
"      Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J Exp Med 1996; 184:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/23\">",
"      M&eacute;nard D, Barnadas C, Bouchier C, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 2010; 107:5967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/24\">",
"      Wertheimer SP, Barnwell JW. Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp Parasitol 1989; 69:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/25\">",
"      Tsuboi T, Kappe SH, al-Yaman F, et al. Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein. Infect Immun 1994; 62:5581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/26\">",
"      Ranjan A, Chitnis CE. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc Natl Acad Sci U S A 1999; 96:14067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/27\">",
"      Singh S, Pandey K, Chattopadhayay R, et al. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. J Biol Chem 2001; 276:17111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/28\">",
"      Miller LH, Haynes JD, McAuliffe FM, et al. Evidence for differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and Plasmodium knowlesi. J Exp Med 1977; 146:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/29\">",
"      Perkins M. Inhibitory effects of erythrocyte membrane proteins on the in vitro invasion of the human malarial parasite (Plasmodium falciparum) into its host cell. J Cell Biol 1981; 90:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/30\">",
"      Breuer WV, Kahane I, Baruch D, et al. Role of internal domains of glycophorin in Plasmodium falciparum invasion of human erythrocytes. Infect Immun 1983; 42:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/31\">",
"      Friedman MJ, Blankenberg T, Sensabaugh G, Tenforde TS. Recognition and invasion of human erythrocytes by malarial parasites: contribution of sialoglycoproteins to attachment and host specificity. J Cell Biol 1984; 98:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/32\">",
"      Pasvol G, Jungery M, Weatherall DJ, et al. Glycophorin as a possible receptor for Plasmodium falciparum. Lancet 1982; 2:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/33\">",
"      Pasvol G, Wainscoat JS, Weatherall DJ. Erythrocytes deficiency in glycophorin resist invasion by the malarial parasite Plasmodium falciparum. Nature 1982; 297:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/34\">",
"      Cartron JP, Prou O, Luilier M, Soulier JP. Susceptibility to invasion by Plasmodium falciparum of some human erythrocytes carrying rare blood group antigens. Br J Haematol 1983; 55:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/35\">",
"      Pasvol G, Chasis JA, Mohandas N, et al. Inhibition of malarial parasite invasion by monoclonal antibodies against glycophorin A correlates with reduction in red cell membrane deformability. Blood 1989; 74:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/36\">",
"      Fischer PR, Boone P. Short report: severe malaria associated with blood group. Am J Trop Med Hyg 1998; 58:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/37\">",
"      Lell B, May J, Schmidt-Ott RJ, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis 1999; 28:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/38\">",
"      Fry AE, Griffiths MJ, Auburn S, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 2008; 17:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/39\">",
"      Cserti-Gazdewich CM, Dhabangi A, Musoke C, et al. Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection. Br J Haematol 2012; 159:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/40\">",
"      Carlson J, Wahlgren M. Plasmodium falciparum erythrocyte rosetting is mediated by promiscuous lectin-like interactions. J Exp Med 1992; 176:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/41\">",
"      Barragan A, Kremsner PG, Wahlgren M, Carlson J. Blood group A antigen is a coreceptor in Plasmodium falciparum rosetting. Infect Immun 2000; 68:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/42\">",
"      Rowe A, Obeiro J, Newbold CI, Marsh K. Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun 1995; 63:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/43\">",
"      Udomsangpetch R, Sueblinvong T, Pattanapanyasat K, et al. Alteration in cytoadherence and rosetting of Plasmodium falciparum-infected thalassemic red blood cells. Blood 1993; 82:3752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/44\">",
"      Chotivanich KT, Udomsangpetch R, Pipitaporn B, et al. Rosetting characteristics of uninfected erythrocytes from healthy individuals and malaria patients. Ann Trop Med Parasitol 1998; 92:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/45\">",
"      Rowe JA, Handel IG, Thera MA, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A 2007; 104:17471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/46\">",
"      Cohen M, Hurtado-Ziola N, Varki A. ABO blood group glycans modulate sialic acid recognition on erythrocytes. Blood 2009; 114:3668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/47\">",
"      Wolofsky KT, Ayi K, Branch DR, et al. ABO blood groups influence macrophage-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes. PLoS Pathog 2012; 8:e1002942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/48\">",
"      Hadley TJ, Klotz FW, Pasvol G, et al. Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion. J Clin Invest 1987; 80:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/49\">",
"      Mitchell GH, Hadley TJ, McGinniss MH, et al. Invasion of erythrocytes by Plasmodium falciparum malaria parasites: evidence for receptor heterogeneity and two receptors. Blood 1986; 67:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/50\">",
"      Mourant AE. Genetical polymorphisms and the incidence of disease. Proc R Soc Med 1968; 61:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/51\">",
"      Mayer DC, Cofie J, Jiang L, et al. Glycophorin B is the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand, EBL-1. Proc Natl Acad Sci U S A 2009; 106:5348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/52\">",
"      Maier AG, Duraisingh MT, Reeder JC, et al. Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med 2003; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/53\">",
"      Jiang L, Duriseti S, Sun P, Miller LH. Molecular basis of binding of the Plasmodium falciparum receptor BAEBL to erythrocyte receptor glycophorin C. Mol Biochem Parasitol 2009; 168:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/54\">",
"      Magowan C, Coppel RL, Lau AO, et al. Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Blood 1995; 86:3196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/55\">",
"      Chishti AH, Palek J, Fisher D, et al. Reduced invasion and growth of Plasmodium falciparum into elliptocytic red blood cells with a combined deficiency of protein 4.1, glycophorin C, and p55. Blood 1996; 87:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/56\">",
"      Lobo CA, Rodriguez M, Reid M, Lustigman S. Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl). Blood 2003; 101:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/57\">",
"      Waller KL, Cooke BM, Nunomura W, et al. Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1). J Biol Chem 1999; 274:23808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/58\">",
"      Senczuk AM, Reeder JC, Kosmala MM, Ho M. Plasmodium falciparum erythrocyte membrane protein 1 functions as a ligand for P-selectin. Blood 2001; 98:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/59\">",
"      Serjeantson SW. A selective advantage for the Gerbich-negative phenotype in malarious areas of Papua New Guinea. P N G Med J 1989; 32:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/60\">",
"      Patel SS, Mehlotra RK, Kastens W, et al. The association of the glycophorin C exon 3 deletion with ovalocytosis and malaria susceptibility in the Wosera, Papua New Guinea. Blood 2001; 98:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/61\">",
"      Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997; 388:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/62\">",
"      Spadafora C, Awandare GA, Kopydlowski KM, et al. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog 2010; 6:e1000968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/63\">",
"      Tham WH, Schmidt CQ, Hauhart RE, et al. Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. Blood 2011; 118:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/64\">",
"      Moulds JM, Zimmerman PA, Doumbo OK, et al. Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood 2001; 97:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/65\">",
"      Thathy V, Moulds JM, Guyah B, et al. Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. Malar J 2005; 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/66\">",
"      Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011; 480:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/67\">",
"      Serjeantson S, Bryson K, Amato D, Babona D. Malaria and hereditary ovalocytosis. Hum Genet 1977; 37:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/68\">",
"      Rosanas-Urgell A, Lin E, Manning L, et al. Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med 2012; 9:e1001305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/69\">",
"      Genton B, al-Yaman F, Mgone CS, et al. Ovalocytosis and cerebral malaria. Nature 1995; 378:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/70\">",
"      O'Donnell A, Allen SJ, Mgone CS, et al. Red cell morphology and malaria anaemia in children with Southeast-Asian ovalocytosis band 3 in Papua New Guinea. Br J Haematol 1998; 101:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/71\">",
"      Kidson C, Lamont G, Saul A, Nurse GT. Ovalocytic erythrocytes from Melanesians are resistant to invasion by malaria parasites in culture. Proc Natl Acad Sci U S A 1981; 78:5829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/72\">",
"      Hadley T, Saul A, Lamont G, et al. Resistance of Melanesian elliptocytes (ovalocytes) to invasion by Plasmodium knowlesi and Plasmodium falciparum malaria parasites in vitro. J Clin Invest 1983; 71:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/73\">",
"      Bunyaratvej A, Butthep P, Kaewkettong P, Yuthavong Y. Malaria protection in hereditary ovalocytosis: relation to red cell deformability, red cell parameters and degree of ovalocytosis. Southeast Asian J Trop Med Public Health 1997; 28 Suppl 3:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/74\">",
"      Miller LH, Hudson D, Rener J, et al. A monoclonal antibody to rhesus erythrocyte band 3 inhibits invasion by malaria (Plasmodium knowlesi) merozoites. J Clin Invest 1983; 72:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/75\">",
"      Mohandas N, Lie-Injo LE, Friedman M, Mak JW. Rigid membranes of Malayan ovalocytes: a likely genetic barrier against malaria. Blood 1984; 63:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/76\">",
"      Apibal S, Suwannurak R, Bunyaratvej A, et al. Increased ovalocytic red cells and their low parasitemia in malaria infected subjects. J Med Assoc Thai 1989; 72:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/77\">",
"      Nagel RL. Red-cell cytoskeletal abnormalities--implications for malaria. N Engl J Med 1990; 323:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/78\">",
"      Glele-Kakai C, Garbarz M, Lecomte MC, et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. Br J Haematol 1996; 95:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/79\">",
"      Dhermy D, Schr&eacute;vel J, Lecomte MC. Spectrin-based skeleton in red blood cells and malaria. Curr Opin Hematol 2007; 14:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/80\">",
"      Gratzer WB, Dluzewski AR. The red blood cell and malaria parasite invasion. Semin Hematol 1993; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/81\">",
"      Schulman S, Roth EF Jr, Cheng B, et al. Growth of Plasmodium falciparum in human erythrocytes containing abnormal membrane proteins. Proc Natl Acad Sci U S A 1990; 87:7339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/82\">",
"      Chishti AH, Maalouf GJ, Marfatia S, et al. Phosphorylation of protein 4.1 in Plasmodium falciparum-infected human red blood cells. Blood 1994; 83:3339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/83\">",
"      Shear HL, Roth EF Jr, Ng C, Nagel RL. Resistance to malaria in ankyrin and spectrin deficient mice. Br J Haematol 1991; 78:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/84\">",
"      Rank G, Sutton R, Marshall V, et al. Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant. Blood 2009; 113:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/85\">",
"      Nash GB, O'Brien E, Gordon-Smith EC, Dormandy JA. Abnormalities in the mechanical properties of red blood cells caused by Plasmodium falciparum. Blood 1989; 74:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24585/abstract/86\">",
"      Paulitschke M, Nash GB. Membrane rigidity of red blood cells parasitized by different strains of Plasmodium falciparum. J Lab Clin Med 1993; 122:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7107 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24585=[""].join("\n");
var outline_f24_0_24585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15309759\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RED CELL SURFACE ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duffy blood group system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Parasite proteins that bind to Duffy antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glycophorin A and other surface antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - ABO(H) blood group system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glycophorin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glycophorin C and the Gerbich antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complement receptor type 1 and Knops blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347495001\">",
"      Basigin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RED CELLS WITH CYTOSKELETAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Southeast Asian ovalocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hereditary elliptocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hereditary spherocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15309759\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=related_link\">",
"      Anemia in malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24586="The genodermatoses";
var content_f24_0_24586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The genodermatoses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Teresa S Wright, MD, FAAD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Susan J Bayliss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/0/24586/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/0/24586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the most commonly encountered inherited skin diseases is presented here. A few rarer disorders are also reviewed because of particular clinical importance in their pathogenesis or treatment. Internet resources that include information about these disorders include GeneClinics (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ) and Mendelian Inheritance in Man (OMIM) (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/projects/omim\">",
"     www.ncbi.nlm.nih.gov/projects/omim",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750729\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genodermatoses are a large group of inherited single-gene disorders with skin manifestations. Many of these disorders are rare. However, the recognition of their skin findings is important not only for the initiation of appropriate dermatologic therapy, but also for the detection of other associated abnormalities in these frequently multisystem disorders, including malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750890\">",
"    <span class=\"h1\">",
"     DISORDERS WITH MALIGNANT POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group of genodermatoses is of particular importance because of the association of skin findings with the development of malignancies, both cutaneous and noncutaneous (",
"    <a class=\"graphic graphic_table graphicRef72060 \" href=\"UTD.htm?3/9/3229\">",
"     table 1",
"    </a>",
"    ). Examples include basal cell nevus syndrome, Gardner syndrome, Peutz-Jeghers syndrome, and Xeroderma pigmentosum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750943\">",
"    <span class=\"h2\">",
"     Basal cell nevus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basal cell nevus syndrome (nevoid basal cell carcinoma syndrome, Gorlin syndrome, MIM #109400) is a rare disorder of autosomal dominant inheritance that results from germline mutations of the human patched gene (PTCH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients have both developmental anomalies and postnatal tumors, especially multiple basal cell carcinomas (BCCs), usually by age 35. Most have the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macrocephaly, frontal bossing and hypertelorism",
"     </li>",
"     <li>",
"      Bifid ribs",
"     </li>",
"     <li>",
"      Palmar and plantar pitting (",
"      <a class=\"graphic graphic_picture graphicRef72687 \" href=\"UTD.htm?25/24/25989\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Odontogenic keratocysts, especially in the mandible, which usually develop in adolescence and typically are the presenting sign of the disorder",
"     </li>",
"     <li>",
"      Medulloblastoma in 3 to 5 percent; meningioma occurs infrequently (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"       \"Epidemiology and clinical features of basal cell carcinoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic appearance of the BCCs in basal cell nevus syndrome does not differ from those seen in sporadic cases. The diagnosis should be suspected in patients who present with multiple BCCs, especially at an early age.",
"   </p>",
"   <p>",
"    These patients require careful sun protection from infancy and regular skin surveillance by a dermatologist. Radiotherapy should be avoided due to the risk of inducing BCCs in the treatment fields.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750950\">",
"    <span class=\"h2\">",
"     Gardner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardner syndrome consists of familial adenomatous polyposis (FAP, MIM #175100) with associated extraintestinal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/4\">",
"     4",
"    </a>",
"    ]. It is inherited as an autosomal dominant disorder caused by mutations in the tumor suppressor gene, adenomatous polyposis coli (APC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"     \"Gardner syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most characteristic skin feature is multiple epidermoid cysts. Other findings include desmoid tumors, lipomas, osteomas (especially of the mandible), supernumerary teeth, gastric polyps, and juvenile nasopharyngeal angiofibromas. Congenital hypertrophy of the retinal pigmented epithelium is a reliable and early marker of the disease when it is present. Prophylactic colectomy is recommended because of the nearly universal development of colorectal cancer in affected patients.",
"   </p>",
"   <p>",
"    In addition to colorectal adenocarcinoma, patients with FAP are at risk for several extracolonic malignancies, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duodenal ampullary carcinoma",
"     </li>",
"     <li>",
"      Follicular or papillary thyroid cancer",
"     </li>",
"     <li>",
"      Childhood hepatoblastoma",
"     </li>",
"     <li>",
"      Gastric carcinoma",
"     </li>",
"     <li>",
"      CNS tumors (mostly medulloblastomas)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750957\">",
"    <span class=\"h2\">",
"     Peutz-Jeghers syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant condition characterized by distinctive mucocutaneous pigmentations and multiple hamartomatous polyps in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/5\">",
"     5",
"    </a>",
"    ]. Most cases are associated with mutations in the tumor suppressor gene STK11",
"    <span class=\"nowrap\">",
"     (serine/threonine",
"    </span>",
"    kinase",
"    <span class=\"nowrap\">",
"     11)/LKB1",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic mucocutaneous pigmentations (lentigines) of PJS are present in more than 95 percent of patients and are caused by pigment-laden macrophages in the dermis. They are typically flat, blue-gray to brown spots 1 to 5 mm in size that look like freckles. However, the onset and location of PJS spots are different from those of freckles.",
"   </p>",
"   <p>",
"    Lentigines occur most commonly on the lips and perioral region (94 percent), hands (74 percent), buccal mucosa (66 percent), and feet (62 percent) (",
"    <a class=\"graphic graphic_picture graphicRef80815 \" href=\"UTD.htm?5/20/5455\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/7\">",
"     7",
"    </a>",
"    ]. They also occur on the nose, perianal area, and genitals, and are rarely found in the intestines. They usually occur during the first one to two years of life, increase in size and number over the ensuing years, and finally fade after puberty, with the exception of those on the buccal mucosa.",
"   </p>",
"   <p>",
"    Gastrointestinal hamartomatous polyps are present in most patients with PJS, and patients may develop gastrointestinal malignancy. The risk of non-gastrointestinal cancers, including adenocarcinomas of the breast, cervix, pancreas, uterus, and ovaries, is also increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750964\">",
"    <span class=\"h2\">",
"     Xeroderma pigmentosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xeroderma pigmentosum (XP) is a rare autosomal recessive disease that occurs in the United States at a frequency of approximately 1:250,000. Mutations have been identified as causative in genes that are involved in nucleotide excision repair of carcinogen adducts after ultraviolet irradiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homozygotes have severe sun sensitivity that leads to development of basal and squamous cell carcinomas and melanomas beginning in early childhood. The incidence of these malignancies for individuals younger than the age of 20 is approximately 2000 times that seen in the general population. Other ocular abnormalities that may be seen include keratitis, opacification of the cornea, iritis with synechia formation, and melanoma of the choroid.",
"   </p>",
"   <p>",
"    Approximately 20 percent of patients with XP have neurologic abnormalities of varying severity caused by primary neuronal degeneration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H25#H25\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523750971\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with particular subtypes of epidermolysis bullosa are at increased risk for cutaneous malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H61550613#H61550613\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Skin cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISORDERS OF KERATINIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratins are intermediate filament proteins that form the cytoskeleton in all epithelial cells, including the stratified epithelium of the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/8\">",
"     8",
"    </a>",
"    ]. Keratins represent the major proteins produced by the keratinocyte, which is the primary cell type of the epidermis. The maturation of basal epidermal cells to the flattened cells that comprise the superficial stratum corneum is known as keratinization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 genes that encode keratins have been identified in humans. The phenotype resulting from a particular mutation depends upon the tissue-specific expression pattern of that keratin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ichthyosiform dermatoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ichthyosiform dermatoses are a diverse group of hereditary skin disorders characterized by the accumulation of \"fish-like\" scales resulting from abnormal epidermal cell kinetics or differentiation (",
"    <a class=\"graphic graphic_table graphicRef71157 \" href=\"UTD.htm?6/30/6637\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The severity of the individual disorders ranges from asymptomatic to life-threatening.",
"   </p>",
"   <p>",
"    The cornerstone of therapy for all types is aggressive hydration of the skin with emollients. When tolerated, keratolytics also may be used. Severe or extensive involvement may require systemic retinoids.",
"   </p>",
"   <p>",
"    Referral to a dermatologist is indicated when basic treatment measures such as emollients are not working, when there are complications related to the skin condition, or if the diagnosis is not clear. Biopsy is useful for certain types of ichthyoses or disorders of cornification.",
"   </p>",
"   <p>",
"    Six common inherited ichthyosiform dermatoses are discussed below. A description of clinical characteristics and diagnostic testing for these and additional disorders is available on the Web site of the Foundation for Ichthyosis and Related Skin Types (",
"    <a class=\"external\" href=\"file://www.scalyskin.org/\">",
"     www.scalyskin.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Ichthyosis vulgaris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ichthyosis vulgaris (MIM #146700) is the mildest form of ichthyosis. It is a relatively common defect that is often not diagnosed. It is thought to occur in 1 in 250 to 300 individuals.",
"   </p>",
"   <p>",
"    The disorder is inherited as an autosomal dominant trait. It is caused by defective synthesis of keratohyalin that results from lack of filaggrin, a major component of the epidermal barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/14\">",
"     14",
"    </a>",
"    ]. This results from mutations in the gene encoding filaggrin, located at chromosome 1q21. Epithelial turnover is normal.",
"   </p>",
"   <p>",
"    Ichthyosis vulgaris typically presents during childhood, usually after three months of age. It is not apparent in the newborn. The disorder typically improves with age.",
"   </p>",
"   <p>",
"    The clinical appearance consists of fine white scales that occur predominantly on the extensor surfaces of the extremities (",
"    <a class=\"graphic graphic_picture graphicRef61258 \" href=\"UTD.htm?33/16/34054\">",
"     picture 3A",
"    </a>",
"    ). Flexures, palms, soles, and the face typically are spared. Palmar markings may be accentuated (hyperlinear). Atopy, including eczema, often is associated. Affected patients may have keratosis pilaris, presenting as follicular hyperkeratosis or chicken-skin, which predominantly affects the trunk, buttocks, and outer aspects of the arms and legs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/15\">",
"     15",
"    </a>",
"    ]. This consists of cornified plugs in the hair follicles that give the skin a stippled appearance when the erector pili muscles are contracted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     X-linked ichthyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked ichthyosis (MIM 308100) is a more serious form of ichthyosis that affects approximately 1 in 6000 males. It is caused by deficiency of steroid sulfatase, secondary to mutations in the gene mapped to Xp22.32 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/16\">",
"     16",
"    </a>",
"    ]. This results in accumulation of cholesterol sulfate and retention hyperkeratosis. Epithelial turnover is normal.",
"   </p>",
"   <p>",
"    The disorder typically presents in the newborn period, with onset at two to six weeks of age, and gradually worsens with age. Because placental steroid sulfatase also is deficient, failure to progress in labor may occur in the mother of an affected fetus, necessitating cesarean delivery. The condition may be detected because of low maternal serum unconjugated estriol during prenatal screening [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical findings consist of large brown adherent scales affecting most body surfaces (",
"    <a class=\"graphic graphic_picture graphicRef66723 \" href=\"UTD.htm?8/8/8322\">",
"     picture 3B",
"    </a>",
"    ). The neck is almost always affected, resulting in a \"dirty\" appearance. The flexures, palms, soles, and face are relatively spared. Asymptomatic corneal opacities occur in at least 50 percent of adult males and may occur in 25 percent of female carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Approximately 12 to 20 percent of boys have cryptorchidism, which is usually bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The risk of testicular cancer is increased in affected patients, independent of cryptorchidism, although the mechanism is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletions that extend to neighboring genes in the distal short arm of the human X chromosome can result in contiguous gene syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/21\">",
"     21",
"    </a>",
"    ], which include: Kallmann syndrome (MIM +308700; hypogonadotropic hypogonadism, anosmia, and a variety of neurological defects) and X-linked chondrodysplasia punctata (CDPX1, MIM #302950) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of secondary hypogonadism in males\", section on 'Kallmann's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lamellar ichthyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lamellar ichthyosis (MIM #242300) is a rare and severe autosomal recessive disorder, affecting approximately 1 in 300,000 live births. It results from mutations in the gene encoding transglutaminase 1, which is responsible for assembly of the cornified envelope [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/24\">",
"     24",
"    </a>",
"    ]. Deficiency of the enzyme results in increased permeability of the skin and excessive transepidermal water loss. Epithelial turnover is increased in the disorder.",
"   </p>",
"   <p>",
"    Affected patients typically present as a \"collodion baby\" at birth, although other disorders may present with this appearance. The infant appears encased in a translucent, taut, parchment-like membrane with underlying generalized erythroderma (",
"    <a class=\"graphic graphic_picture graphicRef62827 \" href=\"UTD.htm?7/1/7187\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/15\">",
"     15",
"    </a>",
"    ]. The covering membrane dries out and gradually is shed, leaving residual erythema and hyperkeratosis. Most infants have ectropion (exposure of the palpebral conjunctiva by eversion of an edge of the eyelid) and eclabium (eversion of the lips). Neonatal complications are due to loss of barrier function of the skin and may include sepsis, electrolyte abnormalities, and protein loss.",
"   </p>",
"   <p>",
"    Affected children and adults develop large brown polygonal scales that involve the entire body surface (",
"    <a class=\"graphic graphic_picture graphicRef59842 \" href=\"UTD.htm?1/10/1189\">",
"     picture 3C",
"    </a>",
"    ), with increased involvement in the flexural folds. Other frequent findings include palmoplantar keratoderma (thickening and scaling of the palms and soles), scarring alopecia, nail dystrophy, and hypohidrosis with heat intolerance. Ectropion is almost always present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Congenital ichthyosiform erythroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital ichthyosiform erythroderma (#242100), also known as nonbullous congenital ichthyosis, is a milder disorder than lamellar ichthyosis. Inheritance is autosomal recessive. It can be caused by mutations in several genes, including the transglutaminase 1 gene, the 12R-lipoxygenase gene, and lipoxygenase 3 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/25\">",
"     25",
"    </a>",
"    ]. Epithelial turnover is increased.",
"   </p>",
"   <p>",
"    Nearly all affected patients present at birth as a collodion baby, similar to lamellar ichthyosis. Children and adults have generalized erythroderma with fine white scaling. Other findings that occur less frequently include palmoplantar keratoderma, scarring alopecia, and persistent ectropion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Epidermolytic ichthyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolytic ichthyosis (EHK, epidermolytic hyperkeratosis, MIM #113800), also known as bullous ichthyosis or bullous congenital ichthyosiform erythroderma, is an autosomal dominant disorder that affects approximately 1 in 300,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/15\">",
"     15",
"    </a>",
"    ]. It is caused by mutations in keratin genes (KRT1 and KRT10). The mutations are spontaneous in approximately 50 percent of cases. Epithelial turnover is increased in the disorder.",
"   </p>",
"   <p>",
"    The condition typically presents in the neonatal period with widespread blistering and erythema. Hyperkeratosis also may be evident at this time. The appearance in children and adults is characterized by generalized hyperkeratosis with dark scales and spiny ridges, most pronounced in flexures. Shedding of scales with full thickness stratum corneum can result in denuded areas of skin. Secondary infection may lead to the development of focal bullae. The blistering generally improves, although the hyperkeratosis remains the same or may worsen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Harlequin ichthyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Harlequin ichthyosis (MIM #242500) is the most severe form of congenital ichthyosis and is often lethal in the perinatal period. Tonofibrils may be increased in the basal layer, and abnormal lamellar granules also are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inheritance is autosomal recessive. Mutations in the ABCA12 gene have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. ABCA12 encodes an adenosine triphosphate-binding cassette (ABC) transporter protein that functions as a lipid transporter within keratinocytes. Mutations in ABCA12 lead to impaired lipid secretion from lamellar granules within the keratinocyte and a defective cutaneous lipid barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The affected infant is encased by massive armor-like plates of scale with deep fissures. The diamond-like configuration of the scales results in the appearance of a harlequin clown (",
"    <a class=\"graphic graphic_picture graphicRef73739 \" href=\"UTD.htm?2/52/2881\">",
"     picture 5",
"    </a>",
"    ). Other features include severe ectropion; eclabium; and deformed or absent ears, nose, fingers, and toes. Many infants are stillborn or die shortly after birth from constriction causing respiratory compromise and the inability to feed, or from sepsis. Long term survival has been reported and may be due to early treatment with",
"    <sup>",
"    </sup>",
"    oral retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/30\">",
"     30",
"    </a>",
"    ]. Survivors undergo phenotypic recovery resembling congenital ichthyosiform erythroderma. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Congenital ichthyosiform erythroderma'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Palmoplantar keratodermas",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders share the common feature of palmar and plantar hyperkeratosis that manifests as thickening and scaling of the palms and soles. The general underlying defect in the majority of the palmoplantar keratodermas is overproduction of a normal or an abnormal keratin in the palms and soles. The majority of cases are mild to moderate, without systemic problems and with autosomal dominant inheritance.",
"   </p>",
"   <p>",
"    The keratodermas differ in their mode of inheritance, severity, and extent of involvement and associated features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This is illustrated by the following examples of these disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Howel-Evans syndrome is a rare autosomal dominant diffuse form with onset between 5 and 15 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/15\">",
"       15",
"      </a>",
"      ]. It has been associated with the early development of esophageal cancer.",
"     </li>",
"     <li>",
"      Vohwinkel syndrome is a rare autosomal dominant disorder in which patients may have autoamputation of the digits (pseudo-ainhum) and high-frequency hearing loss.",
"     </li>",
"     <li>",
"      Papillon-Lef&egrave;vre syndrome is an autosomal recessive condition that presents in the first six months of life. Patients often have severe periodontitis, leading to early dental loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dermatologic management of these disorders includes regular application of emollients and keratolytic agents, and physical removal of excess scale. Oral retinoids also have been beneficial in some cases. Secondary bacterial, viral, or fungal infections are a frequent complicating feature, necessitating appropriate treatment with antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3247114\">",
"    <span class=\"h2\">",
"     Pachyonychia congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pachyonychia congenita is an autosomal dominant disorder caused by mutations in the genes that encode keratins (",
"    <em>",
"     KRT6A",
"    </em>",
"    ,",
"    <em>",
"     KRT6B",
"    </em>",
"    ,",
"    <em>",
"     KRT16",
"    </em>",
"    , and",
"    <em>",
"     KRT17",
"    </em>",
"    ), the type I and II intermediate filament proteins that form a cytoskeletal network in all epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/33\">",
"     33",
"    </a>",
"    ]. In PC, there are focal areas of hyperkeratosis on the soles plus hyperkeratosis of a variety of other tissues where these keratins are expressed, including the nails, oral mucosa, and other sites.",
"   </p>",
"   <p>",
"    Affected patients present within the first year of life with thickened discolored nails of the fingers and toes (",
"    <a class=\"graphic graphic_picture graphicRef52261 \" href=\"UTD.htm?19/46/20193\">",
"     picture 6",
"    </a>",
"    ). Palmar and plantar hyperkeratoses and hyperhidrosis, follicular keratoses of the knees and elbows, and oral leukoplakia also may develop. Thickened nails and plantar hyperkeratoses may be extremely painful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/34\">",
"     34",
"    </a>",
"    ]. Paronychia is a common complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=see_link&amp;anchor=H1#H1\">",
"     \"Paronychia and ingrown toenails\", section on 'Paronychia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Darier disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier disease, also known as Darier-White disease or keratosis follicularis (MIM #124200), is an autosomal dominant disorder caused by mutations in the gene encoding the",
"    <span class=\"nowrap\">",
"     sarco/endoplasmic",
"    </span>",
"    reticulum Ca(+2)-ATPase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/35\">",
"     35",
"    </a>",
"    ]. This results in loss of adhesion between epidermal cells and abnormal keratinization. The disorder is a relatively common genodermatosis with a frequency of up to 1 in 36,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder typically presents in the second decade of life with hyperkeratotic, yellow-brown, greasy-appearing papules that coalesce into verrucous-like plaques (",
"    <a class=\"graphic graphic_picture graphicRef56168 graphicRef70000 \" href=\"UTD.htm?12/54/13161\">",
"     picture 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The lesions are often pruritic and frequently become purulent and malodorous, especially if infected. Typical sites of involvement are in a seborrheic distribution: trunk, face, scalp, and groin. Nails may demonstrate",
"    <span class=\"nowrap\">",
"     red/white",
"    </span>",
"    vertical stripes, subungual hyperkeratosis, and notching of the distal nail margins (",
"    <a class=\"graphic graphic_picture graphicRef81865 \" href=\"UTD.htm?25/36/26178\">",
"     picture 8",
"    </a>",
"    ). Palmar keratosis and pits often are present.",
"   </p>",
"   <p>",
"    The course of the illness is chronic and persistent with characteristic worsening in summer months. Darier disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24776?source=see_link\">",
"     \"Darier disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENETIC BLISTERING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders result from abnormalities in the cohesion of the layers of the epidermis. They result in separation of the layers in response to minimal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa (EB) comprises a clinically and genetically heterogeneous group of rare inherited disorders characterized by marked skin and mucosal fragility caused by mutations in skin structural proteins. There are four major types of EB, based upon the ultrastructural level of tissue cleavage in the skin: EB simplex, junctional EB, dystrophic EB, and Kindler syndrome (",
"    <a class=\"graphic graphic_table graphicRef76897 \" href=\"UTD.htm?23/11/23740\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Many subtypes have been identified based upon clinical, pathophysiological, and molecular criteria (",
"    <a class=\"graphic graphic_table graphicRef77709 graphicRef67202 graphicRef55262 graphicRef81536 \" href=\"UTD.htm?27/19/27955\">",
"     table 4A-D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of EB are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=see_link\">",
"     \"Diagnosis of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3066?source=see_link\">",
"     \"Overview of the management of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PIGMENTATION DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanin, a black or brown pigment formed from tyrosine, is responsible for the color of skin and hair [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/41\">",
"     41",
"    </a>",
"    ]. Melanin is synthesized in melanocytes, which are specialized, dendritic secretory cells derived from the neural crest. These cells migrate to the basal layer of the epidermis during embryogenesis. The presence of melanin in the epidermis helps provide protection from ultraviolet radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders include decreased and excessive pigmentation. Diagnosis is based on the clinical features in most cases, although some may be clarified with molecular testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Oculocutaneous albinism (OCA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculocutaneous albinism (OCA) consists of four autosomal recessive disorders caused by absent or reduced melanin synthesis in the melanocytes, resulting in hypopigmentation of the hair, skin, and eyes. The current classification of albinism is determined by the affected gene (",
"    <a class=\"graphic graphic_table graphicRef70579 \" href=\"UTD.htm?34/43/35515\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common forms are type 1 (OCA1) and type 2 (OCA2). In these conditions, normal numbers of melanocytes are present in the skin. However, there is defective production of melanin from its precursor, tyrosine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     OCA type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCA type 1, also known as tyrosinase-negative albinism, is caused by mutations in the tyrosinase gene located at chromosome 11q14-q21, and is divided clinically into 2 types: type IA (MIM #203100), characterized by complete lack of tyrosinase activity due to production of an inactive enzyme, and type IB (MIM #606952), characterized by reduced activity of tyrosinase.",
"   </p>",
"   <p>",
"    Individuals with OCA1 are unable to produce any melanin. The less severe form (type 1B) is a result of mutations that result in reduced tyrosinase activity. Affected patients typically have snow-white hair, white or pink skin color, and blue eyes. They may develop multiple pink-red nevi and solar keratoses. The development of squamous cell cancers is almost inevitable without aggressive photoprotection. Basal cell cancers and melanomas are common, as well. Ocular problems frequently are severe and include significantly impaired visual acuity, severe nystagmus, photophobia, and strabismus. Compulsory ophthalmologic care is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     OCA type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCA type 2 (MIM #203200) is caused by mutations in the OCA2 gene, formerly known as the P-gene, at chromosome 15q11-q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/44\">",
"     44",
"    </a>",
"    ]. The gene is thought to encode small molecule transporters that may be involved in the biogenesis of melanosomes and transport of tyrosinase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCA type 2 (also known as tyrosinase-positive albinism) is the most common type of albinism throughout the world, with high frequency in equatorial Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder is characterized by decreased amounts of melanin in skin, hair, and eyes, resulting in a generalized pink to cream skin color, yellow-brown hair color, and blue to yellow-brown irides. The ocular and dermatologic manifestations are similar to OCA type 1, but typically are less severe. In this form, skin and hair pigmentation and eye manifestations may improve with time. Pigmented nevi or freckles may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H2#H2\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Lentigo'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1076568199\">",
"    <span class=\"h3\">",
"     OCA type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCA type 3 (MIM #203290) is caused by mutations in tyrosinase-related protein 1 gene (TYRP1) at chromosome 9p23. TYRP1 is an enzyme in the melanin biosynthesis pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCA type 3 presents with either the rufous (red) or the brown OCA phenotype in African and African American patients. These have a copper-red skin and hair color, and diluted iris color. Caucasian patients with OCA type 3 are clinically similar to patients with OCA type 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1076568207\">",
"    <span class=\"h3\">",
"     OCA type 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCA type 4 (MIM #606574) is caused by mutations in the membrane-associated transporter protein gene (MATP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/49\">",
"     49",
"    </a>",
"    ]. OCA type 4 is a rare variant, more common among East Asian populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ocular albinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular albinism is albinism in which the hypopigmentation is primarily limited to the eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. It is less common than oculocutaneous albinism.",
"   </p>",
"   <p>",
"    Ocular albinism type 1 (OA1, MIM #300500), also known as Nettleship-Falls ocular albinism, is the most common form of ocular albinism and has X-linked recessive inheritance. It has an estimated prevalence of 1 in 50,000 to 150,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of OA1 are variable. In affected males, clinical features may include mild cutaneous hypopigmentation, hypopigmentation of the iris and retina, foveal hypoplasia, prominent choroidal vessels, nystagmus, strabismus, head nodding, photophobia, impaired vision, and abnormal crossing of the optic fibers resulting in deficient stereoscopic vision [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/51,54,55\">",
"     51,54,55",
"    </a>",
"    ]. Female carriers may have a patchy distribution of retinal pigmentation resulting from X-inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/51,56\">",
"     51,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OA1 is diagnosed by careful analysis of the family pedigree for X-linked inheritance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular analysis of the OA1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/56\">",
"     56",
"    </a>",
"    ]. The severity of OA1 appears to be related to ethnic background, with individuals from lightly pigmented racial groups more severely affected than those from darkly pigmented groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Life expectancy is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OA1 has been associated with late-onset sensorineural deafness. This form (OASD, MIM 300650) is probably a contiguous gene defect that includes the OA1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Another form of ocular albinism with sensorineural deafness has been linked to chromosome 11 and has autosomal recessive inheritance; this form is also known as Waardenburg syndrome type II (MIM 103470) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Waardenburg syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ocular albinism type II (OA2, MIM #300600), also known as Forsius-Eriksson type ocular albinism and Aland Island eye disease, is a rare X-linked disorder with clinical manifestations that include nystagmus, myopia, astigmatism, foveal hypoplasia, reduced visual acuity, pigmentary changes in the retina, and changes in color vision; the optic nerves are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Piebaldism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Piebaldism (piebald trait) is a rare autosomal dominant disorder in which cell proliferation and migration of neural-crest-derived melanoblasts are defective. This leads to an abnormal distribution of melanocytes during embryogenesis and results in patchy areas of depigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/63\">",
"     63",
"    </a>",
"    ]. The disorder is caused by mutations in the cell-surface receptor tyrosine kinase gene (KIT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients have patches of depigmented skin with hyperpigmented borders occurring principally on the midforehead, neck, anterior trunk, and mid-extremities (",
"    <a class=\"graphic graphic_picture graphicRef58857 graphicRef52591 graphicRef71514 \" href=\"UTD.htm?37/43/38584\">",
"     picture 9A-C",
"    </a>",
"    ). Normal pigmentation occurs on the hands, feet, back, shoulders, and hips. A white forelock is a common finding. The depigmentation is stable and permanent. Patients with piebaldism are generally otherwise healthy and have normal life spans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Waardenburg syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waardenburg syndrome is another autosomal dominant inherited pigmentary disorder in which abnormal distribution of melanocytes during embryogenesis results in patchy areas of depigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/63,65,66\">",
"     63,65,66",
"    </a>",
"    ]. Several forms of Waardenburg syndrome are described. All have the clinical features of type 1, which is characterized by a piebald-like distribution of patchy depigmentation of the hair and skin. Other distinctive noncutaneous features include pigmentary abnormalities of the iris (heterochromia irides) and a broad nasal root, secondary to lateral displacement of the inner canthi of the eyes (",
"    <a class=\"graphic graphic_picture graphicRef56776 \" href=\"UTD.htm?33/18/34084\">",
"     picture 10",
"    </a>",
"    ). Congenital deafness occurs in one in five patients with Waardenburg syndrome and, conversely, an estimated 2 to 35 percent of cases of congenital deafness results from the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Waardenburg syndrome type 1 and type 3 are caused by mutations in the gene for one of three transcription factors PAX3, whereas type 2 is caused by mutations in the transcription factor MITF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/68\">",
"     68",
"    </a>",
"    ]. Waardenburg syndrome type 4 (MIM #277580) also has features of Hirschsprung disease. This type is a result of biallelic mutation in the genes for the endothelin-B receptor or its ligand endothelin-B [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], or heterozygous mutation in the SOX10 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29839266\">",
"    <span class=\"h1\">",
"     NEUROCUTANEOUS SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurocutaneous genetic disorders, also called phakomatoses, may present with a variety of neurologic and cutaneous findings. Examples include the neurofibromatoses and tuberous sclerosis complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neurofibromatosis type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is an autosomal dominant neurocutaneous disorder with nervous system, skeletal, and dermatologic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/72\">",
"     72",
"    </a>",
"    ]. It is caused by mutations in the NF1 gene, encoding the protein neurofibromin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic skin findings that contribute to establishing the diagnosis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six or more cafe-au-lait macules of greatest diameter &gt;5 mm in prepubertal and &gt;15 mm in postpubertal individuals (",
"      <a class=\"graphic graphic_picture graphicRef69606 \" href=\"UTD.htm?11/56/12163\">",
"       picture 11A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Two or more neurofibromas of any type or one plexiform neurofibroma (",
"      <a class=\"graphic graphic_picture graphicRef82613 \" href=\"UTD.htm?31/6/31845\">",
"       picture 11B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Freckling in the axillary or inguinal regions (Crowe sign) (",
"      <a class=\"graphic graphic_picture graphicRef67532 \" href=\"UTD.htm?20/12/20674\">",
"       picture 11C",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neurofibromatosis type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type 2 (NF2) is the central form of neurofibromatosis and is characterized by bilateral vestibular schwannomas (acoustic neuromas), meningiomas of the brain, and",
"    <span class=\"nowrap\">",
"     schwannomas/neurilemmomas",
"    </span>",
"    of the dorsal roots of the spinal cord. The disorder typically presents in the teens or soon after puberty with unilateral hearing loss. In contrast to NF1, cafe-au-lait spots in NF2 are typically few, large, and relatively light in color [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/73\">",
"     73",
"    </a>",
"    ]. NF2 is caused by mutations in the gene encoding the intracellular membrane-associated protein neurofibromin-2 (NF-2), a tumor suppressor, which is also known as merlin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Tuberous sclerosis complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder whose skin findings are often the first clues to its diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. TSC is caused by mutations in one of two genes: TSC1, which encodes hamartin, and TSC2, which encodes tuberin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is estimated that more than 95 percent of patients with TSC have one of the characteristic skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/76\">",
"     76",
"    </a>",
"    ]. The most common lesions are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypopigmented macules, also known as ash-leaf spots, which are usually elliptical in shape (",
"      <a class=\"graphic graphic_picture graphicRef61601 \" href=\"UTD.htm?26/39/27263\">",
"       picture 12A",
"      </a>",
"      ). These are often present at birth, although a Wood's lamp examination may be required to visualize them.",
"     </li>",
"     <li>",
"      Angiofibromas, previously called adenoma sebaceum, which typically involve the malar regions of the face (",
"      <a class=\"graphic graphic_picture graphicRef54868 \" href=\"UTD.htm?27/46/28384\">",
"       picture 12B",
"      </a>",
"      ) and usually become apparent by late childhood or early adolescence.",
"     </li>",
"     <li>",
"      Shagreen patches (connective tissue nevi), seen most commonly over the lower trunk.",
"     </li>",
"     <li>",
"      A distinctive brown, fibrous plaque on the forehead, which may be the first and most readily recognized feature of TSC to appear on physical examination of affected neonates and infants (",
"      <a class=\"graphic graphic_picture graphicRef78688 \" href=\"UTD.htm?6/4/6208\">",
"       picture 13",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ataxia-telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-telangiectasia (AT, also known as Louis-Bar syndrome) is an autosomal recessive disorder caused by mutations in the gene designated ATM (",
"    <strong>",
"     AT",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     M",
"    </strong>",
"    utated). The ATM gene product has one region similar to that of phosphatidylinositol (PI)-3 kinases and another region similar to DNA",
"    <span class=\"nowrap\">",
"     repair/cell",
"    </span>",
"    checkpoint genes. It is expressed in all tissues in the body. ATM is involved in the detection of DNA damage and plays an important role in cell cycle progression. The pathogenesis of AT is thought to be a defect in DNA repair resulting in increased sensitivity to ionizing radiation, immunodeficiency, and progressive cerebellar Purkinje cell death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AT suffer from progressive cerebellar ataxia and other neurologic abnormalities, oculocutaneous telangiectasias, and immune deficiency. Associated features are an increased incidence of malignancy, radiation sensitivity, and diabetes mellitus caused by insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of this disorder typically is suggested by the development of telangiectasias, often first on the bulbar conjunctivae, in a young child (age three to five years) with ataxia. Affected children subsequently develop telangiectasias of the ear, eyelids, cheeks, neck, upper chest, and forearms. Truncal ataxia frequently presents in infancy; many affected individuals are confined to a wheelchair by the second decade.",
"   </p>",
"   <p>",
"    Noninfectious granulomatous papules or plaques have been seen on the skin of affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The relentless downhill course often is complicated by recurrent sinopulmonary infections, progressive cerebellar involvement, lymphoreticular cancer, and death in the second decade of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29839329\">",
"    <span class=\"h1\">",
"     VASCULAR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited syndromes associated with cutaneous vascular abnormalities include ataxia-telangiectasia and hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DISORDERS OF CONNECTIVE TISSUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of connective tissue are frequently expressed in the skin. Thus, multisystem inherited connective tissue disorders such as Ehlers-Danlos syndrome, Marfan syndrome, and osteogenesis imperfecta can be classified as genodermatoses. Pseudoxanthoma elasticum and focal dermal hypoplasia are less common connective tissue disorders with prominent skin abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pseudoxanthoma elasticum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoxanthoma elasticum (PXE, also called Gronblad-Strandberg syndrome, MIM #264800 and #177850) is a genetic disorder of abnormal elastic tissue (fragmentation of elastic fibers) and calcification. Inherited forms are autosomal recessive but sporadic forms have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/79\">",
"     79",
"    </a>",
"    ]. The underlying defect is a mutation in the ABCC6 gene on chromosome 16 that encodes an ATP-binding cassette transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of the disorder varies from childhood to early adulthood, although the characteristic skin findings may be subtle in children. The primary organ systems involved include the skin, eyes, and cardiovascular systems; gastrointestinal bleeding also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/83-85\">",
"     83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive skin lesions develop in 80 percent of individuals before age 20 years. The characteristic skin findings are 2 to 5 mm yellow to orange papules, which may coalesce into irregularly shaped plaques surrounded by normal skin. Because such lesions have a pebbly appearance and are yellow, they are named pseudoxanthomas. The texture of the skin has been likened to plucked-chicken skin. Lesions occur most commonly in flexural areas such as the neck and axillary folds, periumbilical region, and on the inner lower lip (",
"    <a class=\"graphic graphic_picture graphicRef80952 graphicRef59135 graphicRef70421 graphicRef76225 \" href=\"UTD.htm?35/23/36218\">",
"     picture 14A-D",
"    </a>",
"    ). The involved skin may eventually become lax and redundant.",
"   </p>",
"   <p>",
"    The primary ocular finding is that of angioid streaks, representing tears in Bruch's membrane, but this finding is seen in other disorders, as well (",
"    <a class=\"graphic graphic_picture graphicRef77863 \" href=\"UTD.htm?31/8/31873\">",
"     picture 14E",
"    </a>",
"    ). Macular degeneration and retinal deformities contribute to loss of central vision. Severe vision loss occurs in 3 to 8 percent of patients.",
"   </p>",
"   <p>",
"    Common cardiovascular manifestations include accelerated atherosclerosis, which is thought to result from calcification of the internal elastic laminae. These changes can result in myocardial infarction, cerebrovascular disease, and renovascular hypertension at a young age, and result in a shortened life expectancy.",
"   </p>",
"   <p>",
"    The diagnosis of PXE is based upon the clinical appearance and findings on histologic examination of lesional skin. Treatment consists of close ophthalmologic management, monitoring and treatment of any cardiovascular symptoms, and dietary consultation. Because of the risk of ocular disease, patients should be educated to avoid contact sports and straining (eg, weight lifting) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/85\">",
"     85",
"    </a>",
"    ]. They should be referred for genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29839606\">",
"    <span class=\"h1\">",
"     X-LINKED DOMINANT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incontinentia pigmenti, focal dermal hypoplasia, congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD syndrome, MIM #308050), and chondrodysplasia punctata (Conradi-H&uuml;nermann-Happle syndrome, MIM #302960) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] are examples of X-linked dominant disorders with cutaneous manifestations. Incontinentia pigmenti and focal dermal hypoplasia are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29839499\">",
"    <span class=\"h2\">",
"     Incontinentia pigmenti",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incontinentia pigmenti (IP), also known as Bloch-Sulzberger syndrome (MIM #308300), is a rare genodermatosis that presents in the neonatal period. It is an X-linked dominant disorder caused by mutations in the gene known as NEMO (NF-kappa essential modulator, also known as IKK-gamma) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. The gene encodes a regulatory component of the IkappaB kinase complex required to activate the NF-kappaB pathway, which is important for many immune, inflammatory, and apoptotic processes.",
"   </p>",
"   <p>",
"    The disease typically is lethal in males prenatally. Thus, 97 percent of affected infants are female. Survival in male patients may be related to genetic heterogeneity or postzygotic mosaicism. In polymerase chain reaction analysis of samples from 18 boys with clinical and histologic features of IP, 15 had the normal NEMO allele in leukocyte DNA, whereas three had both the normal NEMO allele and the NEMO mutation that occurs in the majority of girls with IP, confirming postzygotic mosaicism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin lesions develop in four stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affected newborns have linear papules and vesicles (",
"      <a class=\"graphic graphic_picture graphicRef58769 \" href=\"UTD.htm?12/38/12897\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      These lesions progress within weeks or months to verrucous streaks, which typically resolve.",
"     </li>",
"     <li>",
"      At three to six months of age, hyperpigmented whorls and swirls appear along Blaschko lines (lines along which skin and appendages, such as hair, melanocytes, and eccrine glands, migrate during embryogenesis).",
"     </li>",
"     <li>",
"      By the second or third decade of life or sooner, the hyperpigmented whorls may gradually become hypopigmented and may show subtle atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Associated findings include scarring alopecia, dystrophic nail changes, and adontia or conical deformities of the teeth. Affected individuals may develop serious ophthalmologic problems, such as strabismus, cataracts, and retinal vascular changes leading to blindness. Central nervous system manifestations that occur in approximately one-third of affected patients include seizures, intellectual disability (mental retardation), and spastic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early stages of disease, abundant eosinophils are seen on skin biopsy. Peripheral eosinophilia typically is present in early infancy. Molecular-based diagnosis is available by demonstrating mutations in NEMO (NF-kappaB essential modulator) that occur in 85 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Focal dermal hypoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal dermal hypoplasia, also known as Goltz syndrome, is a rare but serious multisystem connective tissue genodermatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/92\">",
"     92",
"    </a>",
"    ]. The disorder is X-linked dominant; 90 percent of those affected are female. The mutation is often lethal in males. All cases in surviving males have been due to de novo mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/93\">",
"     93",
"    </a>",
"    ]. This suggests possible X-chromosome inactivation and somatic mosaicism. Focal dermal hypoplasia has been associated with heterozygous and mosaic mutations in PORCN, a member of the porcupine gene family, which encodes endoplasmic reticulum proteins that are involved in Wnt protein secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dermatologic features include linear or serpiginous streaks of dermal hypoplasia associated with pigmentary changes, telangiectasias, and yellowish-brown nodules of fat herniation (",
"    <a class=\"graphic graphic_picture graphicRef55714 \" href=\"UTD.htm?23/52/24386\">",
"     picture 16",
"    </a>",
"    ). The lesions often follow the lines of Blaschko. Papillomas of the lips, perineum, axilla, and periumbilical area also may be seen.",
"   </p>",
"   <p>",
"    Noncutaneous manifestations of the disorder include asymmetric skeletal development. Severe skeletal deformities, such as \"lobster-claw\" hands, often occur. Ocular, dental, and craniofacial abnormalities also may be seen. Approximately 15 percent of affected individuals have mild intellectual disability (mental retardation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     ECTODERMAL DYSPLASIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ectodermal dysplasia are a large group of inherited disorders that manifest as developmental abnormalities of the skin and its appendages, such as hair, nails, teeth, and sweat glands, and other ectodermal structures. Examples include anhidrotic ectodermal dysplasia, hidrotic ectodermal dysplasia, and ankyloblepharon-ectodermal defects-cleft",
"    <span class=\"nowrap\">",
"     lip/palate.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Anhidrotic ectodermal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anhidrotic",
"    ectodermal dysplasia, also known as hypohidrotic ectodermal dysplasia (EDA or HED, MIM #305100), is an X-linked disorder thought to result from an embryologic defect in ectodermal development. The disorder has been associated with mutations in at least three genes that also are involved in the activation of the transcription factor NF-kappa B, which regulates the expression of genes that control immune and stress responses, inflammatory reaction, cell adhesion, and protection against apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/91,96\">",
"     91,96",
"    </a>",
"    ]. These genes are ectodysplasin (EDA1), EDA-receptor (EDAR), which can be inherited in an autosomal dominant or autosomal recessive fashion with indistinguishable clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/97\">",
"     97",
"    </a>",
"    ], and EDAR-associated death domain (EDARADD), which is an allelic variant.",
"   </p>",
"   <p>",
"    Anhidrotic ectodermal dysplasia is characterized by partial or complete absence of the eccrine sweat glands, resulting in reduced or absent sweating. The disorder typically presents with life-threatening hyperpyrexia and heat intolerance. Patients also have characteristic facies with prominent frontal bossing, a saddle nose, sunken cheeks, protruding lips, and sparse hair (",
"    <a class=\"graphic graphic_picture graphicRef80851 \" href=\"UTD.htm?13/61/14289\">",
"     picture 17A",
"    </a>",
"    ). Hypodontia, conical \"peg teeth,\" or anodontia also are frequently seen (",
"    <a class=\"graphic graphic_picture graphicRef66563 \" href=\"UTD.htm?23/58/24481\">",
"     picture 17B",
"    </a>",
"    ). The nails are generally thin and ridged. Female carriers of the disease may have minor abnormalities. Growth abnormalities, particularly decreased weight, are common [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is usually based upon clinical features, although molecular testing is available. Skin biopsy, performed in the past to quantify sweat glands, is not necessary.",
"   </p>",
"   <p>",
"    Treatment is difficult and is directed at maintaining temperature stability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/99\">",
"     99",
"    </a>",
"    ]. Physical exertion and warm climates should be avoided. Cooling vests and water spray misters may be helpful in warm environments. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Hypohidrotic ectodermal dysplasia with immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID, MIM #300291) is caused by mutations in the gene known as NEMO (NF-kappa essential modulator, also known as IKK-gamma). It is typically an X-linked recessive trait but also can be inherited in an autosomal dominant or autosomal recessive fashion. This disorder is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H18#H18\">",
"     \"Combined immunodeficiencies\", section on 'Defects of NF-kappa-B regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Hidrotic ectodermal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hidrotic ectodermal dysplasia is an autosomal dominant condition that is more common and generally less severe than its anhidrotic counterpart. It is caused by mutations in the GJB6 gene, which encodes connexin 30, a component of the gap junction complex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Hidrotic ectodermal dysplasia is most common in the French-Canadian and French populations.",
"   </p>",
"   <p>",
"    The disorder is characterized by slowly growing dystrophic nails, patchy alopecia, and hyperkeratotic palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/102\">",
"     102",
"    </a>",
"    ]. Eccrine sweat glands are present and active. Facial features are normal. Height and weight may be diminished compared to the reference population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Ankyloblepharon-ectodermal defects-cleft lip/palate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankyloblepharon-ectodermal defects-cleft",
"    <span class=\"nowrap\">",
"     lip/palate",
"    </span>",
"    is an autosomal dominant disorder (AEC, MIM #106260). It is also known as Hay-Wells syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/0/24586/abstract/103\">",
"     103",
"    </a>",
"    ]. It is caused by mutations in the sterile alpha motif (SAM) domain of the p63 gene, which is a tumor protein shown to have strong homology to the tumor suppressor p53 and produces six isoforms found in proliferating basal cells of epithelial tissue.",
"   </p>",
"   <p>",
"    Clinically, infants present with erythroderma and erosions, especially of the scalp. Infants are particularly at risk for dehydration, electrolyte imbalances, and infections related to skin erosions. Another classic finding in the neonatal period is ankyloblepharon filiforme adnatum, which are fine interpalpebral strands of tissue that lyse spontaneously in most cases. The skin findings eventuate into chronic ichthyosiform scaling, sparse hair with scarring alopecia, nail dystrophy, and heat intolerance.",
"   </p>",
"   <p>",
"    Treatment is focused on skin care. Trauma or debridement of wounds should be limited. Gentle wound care with bland emollients and silicone-based dressings is recommended. Topical corticosteroids may be helpful in suppressing itching and inflammation. Antimicrobials should be used as necessary for secondary infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5358994\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genodermatoses are a heterogeneous group of rare inherited single-gene disorders with skin manifestations. Recognition is important for the initiation of appropriate dermatologic therapy and detection of other associated abnormalities, including malignancy. (See",
"      <a class=\"local\" href=\"#H523750729\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genodermatoses associated with the development of cutaneous and noncutaneous malignancies include basal cell nevus syndrome (",
"      <a class=\"graphic graphic_picture graphicRef72687 \" href=\"UTD.htm?25/24/25989\">",
"       picture 1",
"      </a>",
"      ), Gardner syndrome, Peutz-Jeghers syndrome (",
"      <a class=\"graphic graphic_picture graphicRef80815 \" href=\"UTD.htm?5/20/5455\">",
"       picture 2",
"      </a>",
"      ), and xeroderma pigmentosum (",
"      <a class=\"graphic graphic_table graphicRef72060 \" href=\"UTD.htm?3/9/3229\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H523750890\">",
"       'Disorders with malignant potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Keratins form the cytoskeleton in epithelial cells. Disorders of keratinization include the ichthyosiform dermatoses (",
"      <a class=\"graphic graphic_table graphicRef71157 \" href=\"UTD.htm?6/30/6637\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61258 graphicRef66723 graphicRef59842 \" href=\"UTD.htm?31/5/31834\">",
"       picture 3A-C",
"      </a>",
"      ), palmoplantar keratodermas (",
"      <a class=\"graphic graphic_picture graphicRef52261 \" href=\"UTD.htm?19/46/20193\">",
"       picture 6",
"      </a>",
"      ), pachyonychia congenita, and Darier disease (",
"      <a class=\"graphic graphic_picture graphicRef56168 graphicRef70000 \" href=\"UTD.htm?12/54/13161\">",
"       picture 7A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Disorders of keratinization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in the cohesion of the layers of the epidermis underlie the congenital blistering disorders (ie, the epidermolysis bullosa syndromes), in which blister formation occurs with little or no trauma (",
"      <a class=\"graphic graphic_picture graphicRef59364 graphicRef73201 \" href=\"UTD.htm?16/14/16616\">",
"       picture 18A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Epidermolysis bullosa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital defects in melanin synthesis lead to pigmentation disorders. These include oculocutaneous albinism, a group of autosomal recessive disorders resulting in hypopigmentation of the hair, skin, and eyes (",
"      <a class=\"graphic graphic_table graphicRef70579 \" href=\"UTD.htm?34/43/35515\">",
"       table 5",
"      </a>",
"      ); piebaldism; and Waardenburg syndrome (",
"      <a class=\"graphic graphic_picture graphicRef56776 \" href=\"UTD.htm?33/18/34084\">",
"       picture 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pigmentation disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous findings are often a key to the diagnosis of the most common neurocutaneous syndromes: neurofibromatosis (",
"      <a class=\"graphic graphic_picture graphicRef69606 graphicRef82613 graphicRef67532 \" href=\"UTD.htm?22/9/22682\">",
"       picture 11A-C",
"      </a>",
"      ), tuberous sclerosis complex (",
"      <a class=\"graphic graphic_picture graphicRef61601 graphicRef54868 \" href=\"UTD.htm?28/14/28900\">",
"       picture 12A-B",
"      </a>",
"      ), and ataxia telangiectasia. (See",
"      <a class=\"local\" href=\"#H29839266\">",
"       'Neurocutaneous syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inherited syndromes associated with cutaneous vascular abnormalities include ataxia-telangiectasia and hereditary hemorrhagic telangiectasia, also known as Osler-Weber-Rendu syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multisystem inherited connective tissue disorders include Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum (",
"      <a class=\"graphic graphic_picture graphicRef80952 graphicRef59135 graphicRef77863 \" href=\"UTD.htm?20/57/21402\">",
"       picture 14A-B, 14E",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"       \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H33\">",
"       'Pseudoxanthoma elasticum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked disorders with cutaneous manifestations include incontinentia pigmenti (",
"      <a class=\"graphic graphic_picture graphicRef58769 \" href=\"UTD.htm?12/38/12897\">",
"       picture 15",
"      </a>",
"      ) and focal dermal hypoplasia (",
"      <a class=\"graphic graphic_picture graphicRef55714 \" href=\"UTD.htm?23/52/24386\">",
"       picture 16",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29839606\">",
"       'X-linked dominant disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ectodermal dysplasias are inherited diseases involving tissues of ectodermal origin. They include anhidrotic ectodermal dysplasia (",
"      <a class=\"graphic graphic_picture graphicRef80851 graphicRef66563 \" href=\"UTD.htm?32/60/33734\">",
"       picture 17A-B",
"      </a>",
"      ), hypohidrotic ectodermal dysplasia, hidrotic ectodermal dysplasia, and ankyloblepharon-ectodermal defects-cleft",
"      <span class=\"nowrap\">",
"       lip/palate.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Ectodermal dysplasias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Spitz JL. Genodermatoses: A Full-Color Clinical Guide to Genetic Skin Disorders, Williams &amp; Wilkins, New York 1996.",
"    </li>",
"    <li>",
"     Sybert VP. Genetic Skin Disorders, Oxford University Press, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/3\">",
"      Reyes MA, Eisen DB. Inherited syndromes. Dermatol Ther 2010; 23:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/4\">",
"      Perniciaro C. Gardner's syndrome. Dermatol Clin 1995; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/5\">",
"      Griffith CD, Bisset WH. Peutz-Jeghers syndrome. Arch Dis Child 1980; 55:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/6\">",
"      Scott RJ, Crooks R, Meldrum CJ, et al. Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Clin Genet 2002; 62:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/7\">",
"      Utsunomiya J, Gocho H, Miyanaga T, et al. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975; 136:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/8\">",
"      Porter RM, Lane EB. Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 2003; 19:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/9\">",
"      Roop D. Defects in the barrier. Science 1995; 267:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/10\">",
"      Shwayder T, Ott F. All about ichthyosis. Pediatr Clin North Am 1991; 38:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/11\">",
"      Crowe MA, James WD. X-linked ichthyosis. JAMA 1993; 270:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/12\">",
"      Rand RE, Baden HP. The ichthyoses--a review. J Am Acad Dermatol 1983; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/13\">",
"      Williams ML. Ichthyosis: mechanisms of disease. Pediatr Dermatol 1992; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/14\">",
"      G&uuml;nzel S, Weidenthaler B, Hausser I, Anton-Lamprecht I. Keratohyalin granules are heterogeneous in ridged and non-ridged human skin: evidence from anti-filaggrin immunogold labelling of normal skin and skin of autosomal dominant ichthyosis vulgaris patients. Arch Dermatol Res 1991; 283:421.",
"     </a>",
"    </li>",
"    <li>",
"     Hereditary disorders of cornification. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), W.B. Elsevier Saunders, Philadelphia 2006. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/16\">",
"      Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 2010; 62:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/17\">",
"      Keren DF, Canick JA, Johnson MZ, et al. Low maternal serum unconjugated estriol during prenatal screening as an indication of placental steroid sulfatase deficiency and X-linked ichthyosis. Am J Clin Pathol 1995; 103:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/18\">",
"      Lykkesfeldt G, H&oslash;yer H, Ibsen HH, Brandrup F. Steroid sulphatase deficiency disease. Clin Genet 1985; 28:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/19\">",
"      Traupe H, Happle R. Clinical spectrum of steroid sulfatase deficiency: X-linked recessive ichthyosis, birth complications and cryptorchidism. Eur J Pediatr 1983; 140:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/20\">",
"      Lykkesfeldt G, Bennett P, Lykkesfeldt AE, et al. Testis cancer. Ichthyosis constitutes a significant risk factor. Cancer 1991; 67:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/21\">",
"      Ballabio A, Bardoni B, Carrozzo R, et al. Contiguous gene syndromes due to deletions in the distal short arm of the human X chromosome. Proc Natl Acad Sci U S A 1989; 86:10001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/22\">",
"      Hardelin JP, Levilliers J, del Castillo I, et al. X chromosome-linked Kallmann syndrome: stop mutations validate the candidate gene. Proc Natl Acad Sci U S A 1992; 89:8190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/23\">",
"      Happle R. X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet 1979; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/24\">",
"      Elias PM, Schmuth M, Uchida Y, et al. Basis for the permeability barrier abnormality in lamellar ichthyosis. Exp Dermatol 2002; 11:248.",
"     </a>",
"    </li>",
"    <li>",
"     Online Mendelian Inheritance in Man, OMIM &trade;. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/26\">",
"      Akiyama M. Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. Arch Dermatol 2006; 142:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/27\">",
"      Akiyama M, Sugiyama-Nakagiri Y, Sakai K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 2005; 115:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/28\">",
"      Thomas AC, Cullup T, Norgett EE, et al. ABCA12 is the major harlequin ichthyosis gene. J Invest Dermatol 2006; 126:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/29\">",
"      Kelsell DP, Norgett EE, Unsworth H, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 2005; 76:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/30\">",
"      Rajpopat S, Moss C, Mellerio J, et al. Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases. Arch Dermatol 2011; 147:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/31\">",
"      Itin PH, Lautenschlager S. Palmoplantar keratoderma and associated syndromes. Semin Dermatol 1995; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/32\">",
"      Lucker GP, Van de Kerkhof PC, Steijlen PM. The hereditary palmoplantar keratoses: an updated review and classification. Br J Dermatol 1994; 131:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/33\">",
"      Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003; 4:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/34\">",
"      Eliason MJ, Leachman SA, Feng BJ, et al. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/35\">",
"      Sakuntabhai A, Ruiz-Perez V, Carter S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/36\">",
"      Ringpfeil F, Raus A, DiGiovanna JJ, et al. Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation. Exp Dermatol 2001; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/37\">",
"      Burge S. Darier's disease--the clinical features and pathogenesis. Clin Exp Dermatol 1994; 19:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/38\">",
"      Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/39\">",
"      Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/40\">",
"      Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol 2012; 30:70.",
"     </a>",
"    </li>",
"    <li>",
"     Disorders of pigmentation. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), W.B. Elsevier Saunders, Philadelphia 2006. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/42\">",
"      Summers CG. Albinism: classification, clinical characteristics, and recent findings. Optom Vis Sci 2009; 86:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/43\">",
"      Gr&oslash;nskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis 2007; 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/44\">",
"      Rinchik EM, Bultman SJ, Horsthemke B, et al. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 1993; 361:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/45\">",
"      Orlow SJ, Brilliant MH. The pink-eyed dilution locus controls the biogenesis of melanosomes and levels of melanosomal proteins in the eye. Exp Eye Res 1999; 68:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/46\">",
"      Toyofuku K, Valencia JC, Kushimoto T, et al. The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase. Pigment Cell Res 2002; 15:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/47\">",
"      Chen K, Manga P, Orlow SJ. Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell 2002; 13:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/48\">",
"      Toyofuku K, Wada I, Valencia JC, et al. Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. FASEB J 2001; 15:2149.",
"     </a>",
"    </li>",
"    <li>",
"     Brilliant MH. Oculocutaneous Albinism Type 4. In: GeneReviews, Pagon RA, Bird TD, Dolan CR, et al., editors (Eds), University of Washington, Seattle; 1993-, Seattle.",
"    </li>",
"    <li>",
"     King RA, Hearing VJ, Dreel DJ, Oetting WS. Albinism. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.5587.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/51\">",
"      Spritz RA. Molecular genetics of oculocutaneous albinism. Hum Mol Genet 1994; 3 Spec No:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/52\">",
"      Rosenberg T, Schwartz M. X-linked ocular albinism: prevalence and mutations--a national study. Eur J Hum Genet 1998; 6:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/53\">",
"      van Dorp DB. Albinism, or the NOACH syndrome (the book of Enoch c.v. 1-20). Clin Genet 1987; 31:228.",
"     </a>",
"    </li>",
"    <li>",
"     Albinism, ocular, type I;OA1. In: Online Mendelian Inheritance in Man. Johns Hopkins University. www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=300500 (Accessed on November 02, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/55\">",
"      Shen B, Samaraweera P, Rosenberg B, Orlow SJ. Ocular albinism type 1: more than meets the eye. Pigment Cell Res 2001; 14:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/56\">",
"      Oetting WS. New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene. Hum Mutat 2002; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/57\">",
"      O'Donnell FE Jr, Green WR, Fleischman JA, Hambrick GW. X-linked ocular albinism in Blacks. Ocular albinism cum pigmento. Arch Ophthalmol 1978; 96:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/58\">",
"      Shiono T, Tsunoda M, Chida Y, et al. X linked ocular albinism in Japanese patients. Br J Ophthalmol 1995; 79:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/59\">",
"      Lyle WM, Sangster JO, Williams TD. Albinism: an update and review of the literature. J Am Optom Assoc 1997; 68:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/60\">",
"      Winship I, Gericke G, Beighton P. X-linked inheritance of ocular albinism with late-onset sensorineural deafness. Am J Med Genet 1984; 19:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/61\">",
"      Winship IM, Babaya M, Ramesar RS. X-linked ocular albinism and sensorineural deafness: linkage to Xp22.3. Genomics 1993; 18:444.",
"     </a>",
"    </li>",
"    <li>",
"     Albinism, ocular, with sensorineural deafness. In: Online Mendelian Inheritance in Man. Johns Hopkins University www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=103470 (Accessed on November 02, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/63\">",
"      Spritz RA. Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Semin Cutan Med Surg 1997; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/64\">",
"      Syrris P, Heathcote K, Carrozzo R, et al. Human piebaldism: six novel mutations of the proto-oncogene KIT. Hum Mutat 2002; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/65\">",
"      Dourmishev AL, Dourmishev LA, Schwartz RA, Janniger CK. Waardenburg syndrome. Int J Dermatol 1999; 38:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/66\">",
"      Read AP, Newton VE. Waardenburg syndrome. J Med Genet 1997; 34:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/67\">",
"      Nayak CS, Isaacson G. Worldwide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 2003; 112:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/68\">",
"      Potterf SB, Furumura M, Dunn KJ, et al. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet 2000; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/69\">",
"      Edery P, Atti&eacute; T, Amiel J, et al. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 1996; 12:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/70\">",
"      McCallion AS, Chakravarti A. EDNRB/EDN3 and Hirschsprung disease type II. Pigment Cell Res 2001; 14:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/71\">",
"      Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 1998; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/72\">",
"      Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.",
"     </a>",
"    </li>",
"    <li>",
"     Hurwitz S. Clinical Pediatric Dermatology, 2nd ed, WB Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/74\">",
"      Lim JY, Kim H, Kim YH, et al. Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 2003; 302:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/75\">",
"      Kwiatkowski DJ, Short MP. Tuberous sclerosis. Arch Dermatol 1994; 130:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/76\">",
"      Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996; 135:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/77\">",
"      Paller AS, Massey RB, Curtis MA, et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr 1991; 119:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/78\">",
"      Murakawa GJ, McCalmot T, Frieden IJ. Chronic plaques in a patient with ataxia telangiectasia. Cutaneous granulomatous lesions in a patient with AT. Arch Dermatol 1998; 134:1145, 1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/79\">",
"      Ringpfeil F, McGuigan K, Fuchsel L, et al. Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. J Invest Dermatol 2006; 126:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/80\">",
"      Le Saux O, Urban Z, Tschuch C, et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000; 25:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/81\">",
"      Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A 2000; 97:6001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/82\">",
"      Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 2000; 25:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/83\">",
"      Sherer DW, Sapadin AN, Lebwohl MG. Pseudoxanthoma elasticum: an update. Dermatology 1999; 199:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/84\">",
"      Engelman MW, Fliegelman MT. Pseudoxanthoma elasticum. Cutis 1978; 21:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/85\">",
"      Laube S, Moss C. Pseudoxanthoma elasticum. Arch Dis Child 2005; 90:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/86\">",
"      Aradhya S, Woffendin H, Jakins T, et al. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet 2001; 10:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/87\">",
"      Smahi A, Courtois G, Vabres P, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/88\">",
"      Fusco F, Fimiani G, Tadini G, et al. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J Am Acad Dermatol 2007; 56:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/89\">",
"      Sahn EE, Davidson LS. Incontinentia pigmenti: three cases with unusual features. J Am Acad Dermatol 1994; 31:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/90\">",
"      Dutheil P, Vabres P, Cayla MC, Enjolras O. Incontinentia pigmenti: late sequelae and genotypic diagnosis: a three-generation study of four patients. Pediatr Dermatol 1995; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/91\">",
"      Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/92\">",
"      Moore DJ, Mallory SB. Goltz syndrome. Pediatr Dermatol 1989; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/93\">",
"      Goltz RW. Focal dermal hypoplasia syndrome. An update. Arch Dermatol 1992; 128:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/94\">",
"      Grzeschik KH, Bornholdt D, Oeffner F, et al. Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet 2007; 39:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/95\">",
"      Wang X, Reid Sutton V, Omar Peraza-Llanes J, et al. Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat Genet 2007; 39:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/96\">",
"      Carrol ED, Gennery AR, Flood TJ, et al. Anhidrotic ectodermal dysplasia and immunodeficiency: the role of NEMO. Arch Dis Child 2003; 88:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/97\">",
"      Lind LK, Stecks&eacute;n-Blicks C, Lejon K, Schmitt-Egenolf M. EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families. BMC Med Genet 2006; 7:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/98\">",
"      Motil KJ, Fete TJ, Fraley JK, et al. Growth characteristics of children with ectodermal dysplasia syndromes. Pediatrics 2005; 116:e229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/99\">",
"      Masse JF, P&eacute;russe R. Ectodermal dysplasia. Arch Dis Child 1994; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/100\">",
"      Zhang XJ, Chen JJ, Yang S, et al. A mutation in the connexin 30 gene in Chinese Han patients with hidrotic ectodermal dysplasia. J Dermatol Sci 2003; 32:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/101\">",
"      Common JE, Becker D, Di WL, et al. Functional studies of human skin disease- and deafness-associated connexin 30 mutations. Biochem Biophys Res Commun 2002; 298:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/0/24586/abstract/102\">",
"      Chitty LS, Dennis N, Baraitser M. Hidrotic ectodermal dysplasia of hair, teeth, and nails: case reports and review. J Med Genet 1996; 33:707.",
"     </a>",
"    </li>",
"    <li>",
"     Sutton VR. Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate Syndrome. In: GeneReviews [Internet], Pagon RA, Bird TD, Dolan CR, et al. (Eds), University of Washington, Seattle, Seattle; 1993-.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3004 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24586=[""].join("\n");
var outline_f24_0_24586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5358994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523750729\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523750890\">",
"      DISORDERS WITH MALIGNANT POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523750943\">",
"      Basal cell nevus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523750950\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523750957\">",
"      Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523750964\">",
"      Xeroderma pigmentosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523750971\">",
"      Epidermolysis bullosa syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISORDERS OF KERATINIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ichthyosiform dermatoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Ichthyosis vulgaris",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - X-linked ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lamellar ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Congenital ichthyosiform erythroderma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Epidermolytic ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Harlequin ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Palmoplantar keratodermas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3247114\">",
"      Pachyonychia congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Darier disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENETIC BLISTERING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PIGMENTATION DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Oculocutaneous albinism (OCA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - OCA type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - OCA type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1076568199\">",
"      - OCA type 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1076568207\">",
"      - OCA type 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ocular albinism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Piebaldism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Waardenburg syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29839266\">",
"      NEUROCUTANEOUS SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neurofibromatosis type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Tuberous sclerosis complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29839329\">",
"      VASCULAR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DISORDERS OF CONNECTIVE TISSUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pseudoxanthoma elasticum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29839606\">",
"      X-LINKED DOMINANT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29839499\">",
"      Incontinentia pigmenti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Focal dermal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      ECTODERMAL DYSPLASIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Anhidrotic ectodermal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Hypohidrotic ectodermal dysplasia with immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Hidrotic ectodermal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Ankyloblepharon-ectodermal defects-cleft lip/palate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5358994\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/3004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3004|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25989\" title=\"picture 1\">",
"      Palmar pits BCC nevus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/20/5455\" title=\"picture 2\">",
"      Peutz Jeghers oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/16/34054\" title=\"picture 3A\">",
"      Ichthyosis vulgaris 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/8/8322\" title=\"picture 3B\">",
"      X-linked ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/10/1189\" title=\"picture 3C\">",
"      Lamellar ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/1/7187\" title=\"picture 4\">",
"      Collodion baby",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/52/2881\" title=\"picture 5\">",
"      Harlequin fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/46/20193\" title=\"picture 6\">",
"      Pachyonychia congenita - nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24164\" title=\"picture 7A\">",
"      Darier disease - light skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/3/29748\" title=\"picture 7B\">",
"      Darier disease - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/36/26178\" title=\"picture 8\">",
"      Darier disease - nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/21/9553\" title=\"picture 9A\">",
"      Piebaldism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/17/20753\" title=\"picture 9B\">",
"      Piebaldism - forelock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/21/21840\" title=\"picture 9C\">",
"      Piebaldism - trunk and extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/18/34084\" title=\"picture 10\">",
"      Waardenburg syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/56/12163\" title=\"picture 11A\">",
"      Neurofibromata and caf&eacute;-au-lait macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/6/31845\" title=\"picture 11B\">",
"      Multiple neurofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/12/20674\" title=\"picture 11C\">",
"      Axillary freckling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/39/27263\" title=\"picture 12A\">",
"      TSC hypomelanotic macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/46/28384\" title=\"picture 12B\">",
"      TSC angiofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/4/6208\" title=\"picture 13\">",
"      TS forehead plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/44/24261\" title=\"picture 14A\">",
"      Pseudoxanthoma elasticum neck 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/26/35235\" title=\"picture 14B\">",
"      Pseudoxanthoma elasticum neck 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/29/39376\" title=\"picture 14C\">",
"      Pseudoxanthoma elasticum lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/15/18674\" title=\"picture 14D\">",
"      PXE neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/8/31873\" title=\"picture 14E\">",
"      Angioid streaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/38/12897\" title=\"picture 15\">",
"      Incontinentia pigmenti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/52/24386\" title=\"picture 16\">",
"      Focal dermal hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/61/14289\" title=\"picture 17A\">",
"      Anhidrotic ectodermal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/58/24481\" title=\"picture 17B\">",
"      Anhidrotic ectodermal dysplasia - teeth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/12/4291\" title=\"picture 18A\">",
"      Epidermolysis bullosa simplex - hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/60/20419\" title=\"picture 18B\">",
"      Epidermolysis bullosa simplex - feet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/9/3229\" title=\"table 1\">",
"      Genodermatoses and malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/30/6637\" title=\"table 2\">",
"      Ichthyoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23740\" title=\"table 3\">",
"      Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/16/6415\" title=\"table 4A\">",
"      EB simplex variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/28/9678\" title=\"table 4B\">",
"      JEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21662\" title=\"table 4C\">",
"      DEB variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/53/15195\" title=\"table 4D\">",
"      Kindler syndrome 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/43/35515\" title=\"table 5\">",
"      Albinism classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24776?source=related_link\">",
"      Darier disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=related_link\">",
"      Diagnosis of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3066?source=related_link\">",
"      Overview of the management of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_0_24587="Antibiotics C diff PI";
var content_f24_0_24587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial agents that may induce clostridium difficile diarrhea and colitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Frequently associated",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluoroquinolones",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clindamycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Penicillins (broad spectrum)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephalosporins (broad spectrum)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Occasionally associated",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Macrolides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trimethoprim",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Rarely associated",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aminoglycosides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tetracyclines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chloramphenicol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metronidazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vancomycin",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24587=[""].join("\n");
var outline_f24_0_24587=null;
var title_f24_0_24588="Diagnostic value of BAL in ILD";
var content_f24_0_24588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic features of bronchoalveolar lavage in interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Findings in BAL fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Malignancy",
"       </td>",
"       <td>",
"        Lymphangitic carcinomatosis",
"       </td>",
"       <td>",
"        Malignant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchioloalveolar cell carcinoma",
"       </td>",
"       <td>",
"        Malignant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary lymphoma",
"       </td>",
"       <td>",
"        Malignant cells",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Diseases due to inhaled (exogenous) material",
"       </td>",
"       <td rowspan=\"2\">",
"        Lipoid pneumonia",
"       </td>",
"       <td>",
"        Fat globules in macrophages (oil-red-O-stain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multinucleated giant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asbestosis",
"       </td>",
"       <td>",
"        Ferruginous bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silicosis",
"       </td>",
"       <td>",
"        Dust particles seen by polarized microscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berylliosis",
"       </td>",
"       <td>",
"        Positive lymphocyte transformation test to beryllium salts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        Inflammatory",
"       </td>",
"       <td rowspan=\"3\">",
"        Diffuse alveolar hemorrhage",
"       </td>",
"       <td>",
"        Large numbers of erythrocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemosiderin-laden macrophages (iron stain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sequential lavages progressively more hemorrhagic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic eosinophilic pneumonia",
"       </td>",
"       <td>",
"        Eosinophils &ge;40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic acute eosinophilic pneumonia",
"       </td>",
"       <td>",
"        Eosinophils &ge;25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary alveolar proteinosis",
"       </td>",
"       <td>",
"        Lipoproteinaceous material (periodic acid-Schiff stain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Pulmonary Langerhans cell histiocytosis (Histiocytosis X)",
"       </td>",
"       <td>",
"        Monoclonal antibody (T6) positive histiocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD1 positive Langerhans cells &gt;5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birbeck granules in lavaged macrophages (seen by electron microscopy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24588=[""].join("\n");
var outline_f24_0_24588=null;
var title_f24_0_24589="Etiology of diarrhea";
var content_f24_0_24589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of diarrhea by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infants and young children",
"       </td>",
"       <td class=\"subtitle1\">",
"        Older children and adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal infections*",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Viruses",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Bacteria",
"         </span>",
"        </p>",
"        <p>",
"         Parasites",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Viruses",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Bacteria",
"         </span>",
"        </p>",
"        <p>",
"         Parasites",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Non-gastrointestional infections (parenteral diarrhea)",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Otitis media",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Urinary tract infections",
"         </span>",
"        </p>",
"        <p>",
"         Other systemic infections",
"        </p>",
"       </td>",
"       <td>",
"        Systemic infections",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dietary disturbances",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Overfeeding",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Food allergy",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Starvation stools",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         Starvation stools",
"        </span>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Anatomic abnormalities",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"red\">",
"          Intussusception",
"         </span>",
"        </p>",
"        <p>",
"         Hirschsprung disease",
"         <span class=\"red\">",
"          (&plusmn; toxic megacolon)",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Partial bowel obstruction",
"         </span>",
"        </p>",
"        <p>",
"         Blind loop syndrome",
"        </p>",
"        <p>",
"         Intestinal lymphangiectasis",
"        </p>",
"        <p>",
"         Short&nbsp;gut syndrome",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"red\">",
"          Appendicitis",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Partial obstruction",
"         </span>",
"        </p>",
"        <p>",
"         Blind loop syndrome",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Ulcerative colitis",
"         <span class=\"red\">",
"          (&plusmn; toxic megacolon)",
"         </span>",
"        </p>",
"        <p>",
"         Crohn's disease",
"         <span class=\"red\">",
"          (&plusmn; toxic megacolon)",
"         </span>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Malabsorption or increased secretion",
"       </td>",
"       <td>",
"        <p>",
"         Cystic fibrosis",
"        </p>",
"        <p>",
"         Celiac disease",
"        </p>",
"        <p>",
"         Disaccharidase deficiency",
"        </p>",
"        <p>",
"         Acrodermatitis enteropathica",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Celiac disease",
"        </p>",
"        <p>",
"         Disaccharidase deficiency",
"        </p>",
"        <p>",
"         Acrodermatitis enteropathica",
"        </p>",
"        <p>",
"         Secretory neoplasms",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Immunodeficiency",
"       </td>",
"       <td>",
"        <p>",
"         Severe combined immunodeficiencies and other genetic disorders",
"        </p>",
"        <p>",
"         Human immunodeficiency virus infection (HIV)",
"        </p>",
"       </td>",
"       <td>",
"        Human immunodeficiency virus infection (HIV)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Endocrinopathy",
"       </td>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"       <td>",
"        <p>",
"         Hyperthyroidism",
"        </p>",
"        <p>",
"         Hypoparathyroidism",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Antibiotic-associated diarrhea",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Pseudomembranous colitis",
"         </span>",
"        </p>",
"        <p>",
"         Toxins",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Hemolytic uremic syndrome",
"         </span>",
"        </p>",
"        <p>",
"         Neonatal drug withdrawal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span class=\"green\">",
"          Antibiotic-associated diarrhea",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"red\">",
"          Pseudomembranous colitis",
"         </span>",
"        </p>",
"        <p>",
"         Toxins",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Irritable bowel syndrome",
"         </span>",
"        </p>",
"        <p>",
"         <span class=\"green\">",
"          Psychogenic disturbances",
"         </span>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <span style=\"color:#ff0000\">",
"     Red",
"    </span>",
"    : Life-threatening cause.",
"    <br>",
"     <span style=\"color:#008000\">",
"      Green",
"     </span>",
"     : Common cause.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Gary R Fleisher, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24589=[""].join("\n");
var outline_f24_0_24589=null;
var title_f24_0_24590="Dabigatran drug interactions";
var content_f24_0_24590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dabigatran pharmacokinetic interactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Selected interacting drugs and drug classes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management suggestions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendations found in licensed product information*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Antacids, H2 antagonists, proton pump inhibitors (PPIs)",
"       </td>",
"       <td>",
"        Decreased dabigatran concentration (modest effect)",
"       </td>",
"       <td>",
"        Administer dabigatran at least two hours before acid suppressive medications.",
"       </td>",
"       <td>",
"        <p>",
"         US: None.",
"        </p>",
"        <p>",
"         EMA, UK: A PPI, pantoprazole, decreased dabigatran levels by ~30 percent, but differences in clinical outcomes were not detected.",
"        </p>",
"        <p>",
"         CAN: Administer dabigatran at least two hours before antacids. Avoid administration of antacids with dabigatran within 24 hours following surgery.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Inhibitors of P-gp efflux transporter (eg, abiraterone, alfentanil, amiodarone, atorvastatin, azithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        , carvedilol, clarithromycin, cobicistat containing coformulations, conivaptan",
"        <sup>",
"         &bull;",
"        </sup>",
"        , crizotinib, cyclosporine, darunavir, diltiazem",
"        <sup>",
"         &bull;",
"        </sup>",
"        , dipyridamole, dronedarone, duloxetine",
"        <sup>",
"         &bull;",
"        </sup>",
"        , erythromycin, fenofibrate",
"        <sup>",
"         &bull;",
"        </sup>",
"        , grapefruit and grapefruit juice",
"        <sup>",
"         &yen;",
"        </sup>",
"        , indinavir",
"        <sup>",
"         &bull;",
"        </sup>",
"        , itraconazole, ivacaftor, ketoconazole, lapatinib, lopinavir, lovastatin",
"        <sup>",
"         &bull;",
"        </sup>",
"        , mefloquine, mifepristone",
"        <sup>",
"         &bull;",
"        </sup>",
"        , nelfinavir, nicardipine, nifedipine",
"        <sup>",
"         &bull;",
"        </sup>",
"        , nilotinib, posaconazole",
"        <sup>",
"         &bull;",
"        </sup>",
"        , progesterone, propafenone",
"        <sup>",
"         &bull;",
"        </sup>",
"        , propranolol, quinidine, quinine, ranolazine, reserpine, ritonavir, ritonavir containing coformulations, saquinavir, sunitinib, tacrolimus, tamoxifen, telaprevir, telithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        , ticagrelor",
"        <sup>",
"         &bull;",
"        </sup>",
"        , tolvaptan",
"        <sup>",
"         &bull;",
"        </sup>",
"        , ulipristal, vandetanib, vemurafenib, verapamil)",
"       </td>",
"       <td>",
"        Increased dabigatran concentration (variable effect)",
"       </td>",
"       <td>",
"        <p>",
"         Avoid use of ketoconazole, cyclosporine, itraconazole and tacrolimus with dabigatran.",
"        </p>",
"        <p>",
"         Avoid use of",
"         <strong>",
"          any",
"         </strong>",
"         P-gp inhibitor with dabigatran if moderate or severe renal insufficiency (CrCl &lt;50 mL/minute)",
"         <strong>",
"          or",
"         </strong>",
"         in any patient aged &ge;80 years.",
"        </p>",
"        <p>",
"         Where concomitant use of a P-gp inhibitor is necessary, administer dabigatran at least two hours before P-gp inhibitor which may decrease severity of interaction; monitor for signs of excessive anticoagulation.",
"        </p>",
"        <p>",
"         The efficacy of routine coagulation testing to evaluate the degree of anticoagulation with dabigatran is limited and is discussed in the text.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         US: In patients with moderate renal insufficiency (CrCl 30 to 50 mL/minute), consider a dose reduction to 75 mg twice daily if administered with dronedarone or ketoconazole. In patients with severe renal insufficiency (CrCl &lt;30 mL/minute), avoid the use of any inhibitor of P-gp.",
"        </p>",
"        <p>",
"         CAN: Avoid use with dronedarone or ketoconazole (contraindicated); consider avoiding co-treatment with any other strong inhibitor of P-gp, especially in patients aged &gt;75 years, unless medically essential. A reduction of dabigatran dose for VTE prevention following hip or knee surgery is recommended if used with P-gp inhibitors amiodarone, verapamil, or quinidine",
"         <sup>",
"          &Delta;",
"         </sup>",
"         . For prevention of stroke/systemic embolism (SSE) in patients with atrial fibrillation: no alteration of dabigatran dose suggested with amiodarone, quinidine or verapamil. However, give dabigatran two hours before quinidine or verapamil to reduce effect of interaction. A dose reduction may be considered for geriatric patients requiring co-treatment with any P-gp inhibitor",
"         <sup>",
"          &Delta;",
"         </sup>",
"         . Occasional aPTT testing may be considered to rule out excessive anticoagulation.",
"        </p>",
"        <p>",
"         EMA: Use with cyclosporine, itraconazole, ketoconazole or tacrolimus is contraindicated; use with dronedarone and posaconazole not recommended; use caution if co-treatment required with any other strong inhibitor of P-gp (eg, amiodarone, clarithromycin, quinidine, or verapamil). A reduction of dabigatran dose for VTE prevention following hip or knee surgery is recommended if used with strong P-gp inhibitors amiodarone, verapamil, or quinidine",
"         <sup>",
"          &Delta;",
"         </sup>",
"         .",
"        </p>",
"        <p>",
"         UK: Use with cyclosporine, dronedarone, itraconazole, ketoconazole, or tacrolimus is contraindicated; use with posaconazole not recommended; use caution if co-treatment required with any other strong inhibitor of P-gp (eg, amiodarone, clarithromycin, quinidine or verapamil) particularly in patients having mild to moderate renal insufficiency. A reduction of dabigatran dose for VTE prevention following hip or knee surgery is recommended if used with P-gp inhibitors amiodarone, quinidine, or verapamil",
"         <sup>",
"          &Delta;",
"         </sup>",
"         . For prevention of stroke/systemic embolism (SSE) in patients with atrial fibrillation a reduction of dabigatran dose is recommended with verapamil",
"         <sup>",
"          &Delta;",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inducers of P-gp efflux transporter (eg, carbamazepine, dexamethasone, doxorubicin, nefazodone, pentobarbital",
"        <sup>",
"         &bull;",
"        </sup>",
"        , phenobarbital",
"        <sup>",
"         &bull;",
"        </sup>",
"        , prazosin, rifampin",
"        <sup>",
"         &loz;",
"        </sup>",
"        , St. John's wort, tenofovir",
"        <sup>",
"         &sect;",
"        </sup>",
"        , tipranavir, trazodone, vinblastine)",
"       </td>",
"       <td>",
"        Decreased dabigatran concentration (significant effect)",
"       </td>",
"       <td>",
"        <p>",
"         Avoid concurrent use of dabigatran with P-gp inducers.",
"        </p>",
"        <p>",
"         Decreased concentrations of dabigatran may persist for nearly 7 days after stopping use of a potent inducer of P-gp (eg, rifampin",
"         <sup>",
"          &loz;",
"         </sup>",
"         ).",
"        </p>",
"       </td>",
"       <td>",
"        US, CAN, EMA, UK - avoid use with P-gp inducers (eg, carbemazepine, phenytoin, rifampin",
"        <sup>",
"         &loz;",
"        </sup>",
"        or St. John's wort).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Interaction data and recommendations refer to systemic drug forms. For additional information see Lexi-Interact drug interactions program provided with UpToDate.",
"    <div class=\"footnotes\">",
"     CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux transporters; VTE: venous thromboembolism; US: United States Prescribing Information; CAN: Canadian Product Monograph; EMA: European Medicines Agency Summary of Product Characteristics; UK: United Kingdom Summary of Product Characteristics.",
"     <br>",
"      *",
"      <strong>",
"       Drug interactions, management recommendations, and contraindicated drug combinations listed in licensed product information vary by country. Consult official product information for details before using this agent.",
"      </strong>",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Conflicting information on whether this drug significantly alters P-gp transporters.",
"       <br>",
"        &Delta; For detailed information, see Lexicomp drug reference included with UpToDate or national product information.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Rifampicin is the international nonproprietary (generic) name.",
"         <br>",
"          &sect; Classified as a less potent P-gp inducer according to the Canadian product monograph.",
"          <br>",
"           &yen; Avoidance of grapefruit and grapefruit juice in large quantities is advised due to lack of predictability of its effect.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data accessed October 12, 2012:",
"     <br/>",
"     <ol>",
"      <li>",
"       US prescribing information Pradaxa (dabigatran etexilate mesylate) revised May 2012, available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9\" target=\"_blank\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       Canada Product Monograph Pradaxa (dabigatran etexilate mesilate) revision September 5, 2012 available at:",
"       <a href=\"file://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=84384&amp;lang=eng\" target=\"_blank\">",
"        file://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=84384&amp;lang=eng",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       European Medicines Agency Summary of Product Characteristics Pradaxa (dabigatran) updated September 4, 2012 available at:",
"       <a href=\"file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf\" target=\"_blank\">",
"        file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       UK Summary of Product Characteristics Pradaxa updated August, 2012 available at:",
"       <a href=\"file://www.medicines.org.uk/EMC/searchresults.aspx?term=pradaxa&amp;searchtype=QuickSearch\" target=\"_blank\">",
"        file://www.medicines.org.uk/EMC/searchresults.aspx?term=pradaxa&amp;searchtype=QuickSearch",
"       </a>",
"       .",
"      </li>",
"     </ol>",
"     <br/>",
"     Additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Lexicomp online Lexi-Interact Copyright 1978-2013 by Lexicomp, Inc. All rights reserved.",
"      </li>",
"      <li>",
"       Hansten PD, Horn JR. Top 100 drug interactions: guide to patient management, 12th ed, H&amp;H Publications, 2012.",
"      </li>",
"      <li>",
"       Hartter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012; 74:490.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24590=[""].join("\n");
var outline_f24_0_24590=null;
var title_f24_0_24591="Phase contrast micrograph showing dysmorphic red cells in urine";
var content_f24_0_24591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phase contrast micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phase contrast microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_0_24591=[""].join("\n");
var outline_f24_0_24591=null;
